

1 **Gut microbiome shifts in adolescents after sleeve gastrectomy with increased oral-associated**
2 **taxa and pro-inflammatory potential**

3 Cynthia O Akagbosu^{1*}, Kathryn E McCauley^{2*}, Sivaranjani Namasivayam^{3*}, Hector N Romero-
4 Soto³, Wade O'Brien⁴, Mickayla Bacorn³, Eric Bohrnsen⁵, Benjamin Schwarz⁵, Shreni Mistry⁶,
5 Andrew S Burns⁶, P. Juliana Perez-Chaparro⁶, Qing Chen³, Phoebe LaPoint³, Anal Patel³, Lauren
6 E Krausfeldt², Poorani Subramanian², Brian A Sellers⁷, Foo Cheung⁷, Richard Apps⁷, Iyadh
7 Douagi⁷, Shira Levy³, Evan P Nadler^{8**}, Suchitra K Hourigan^{3**}

8 * These authors contributed equally

9 ** These authors contributed equally

- 10 1. Department of Gastroenterology. Weill Cornell Medicine. New York, New York,
11 United States.
- 12 2. Bioinformatics and Computational Biosciences Branch National Institute of Allergy
13 and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United
14 States.
- 15 3. Clinical Microbiome Unit. National Institute of Allergy and Infectious Diseases,
16 National Institutes of Health, Bethesda, Maryland, United States.
- 17 4. Dartmouth Geisel School of Medicine, Dartmouth College, Hanover, New
18 Hampshire, United States.
- 19 5. Research Technologies Branch, National Institute of Allergy and Infectious Diseases,
20 Division of Intramural Research, Rocky Mountain Laboratories, National Institutes of
21 Health, Hamilton, Montana, United States.

- 22 6. NIAID Microbiome Program, National Institute of Allergy and Infectious Diseases,
23 National Institutes of Health, Bethesda, Maryland, United States.
- 24 7. NIH Center for Human Immunology, Autoimmunity, and Inflammation (CHI),
25 Bethesda, Maryland, United States.
- 26 8. Evan P Nadler. ProCare Consultants, Washington DC, Washington DC ,United States.

27 **Corresponding Author:** Suchitra K Hourigan. Clinical Microbiome Unit. National Institute of
28 Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United
29 States. suchitra.hourigan@nih.gov

30 **Word Count:** 3999

31

32

33

34

35

36

37

38

39

40

41

42 **ABSTRACT**

43 Background: Bariatric surgery is highly effective in achieving weight loss in children and
44 adolescents with severe obesity, however the underlying mechanisms are incompletely understood,
45 and gut microbiome changes are unknown.

46 Objectives: 1) To comprehensively examine gut microbiome and metabolome changes after
47 laparoscopic vertical sleeve gastrectomy (VSG) in adolescents and 2) to assess whether the
48 microbiome/metabolome changes observed with VSG influence phenotype using germ-free
49 murine models.

50 Design: 1) A longitudinal observational study in adolescents undergoing VSG with serial stool
51 samples undergoing shotgun metagenomic microbiome sequencing and metabolomics (polar
52 metabolites, bile acids and short chain fatty acids) and 2) a human-to-mouse fecal transplant study.

53 Results: We show adolescents exhibit significant gut microbiome and metabolome shifts several
54 months after VSG, with increased alpha diversity and notably with enrichment of oral-associated
55 taxa. To assess causality of the microbiome/metabolome changes in phenotype, pre-VSG and post-
56 VSG stool was transplanted into germ-free mice. Post-VSG stool was not associated with any
57 beneficial outcomes such as adiposity reduction compared pre-VSG stool. However, post-VSG
58 stool exhibited an inflammatory phenotype with increased intestinal Th17 and decreased
59 regulatory T cells. Concomitantly, we found elevated fecal calprotectin and an enrichment of
60 proinflammatory pathways in a subset of adolescents post-VSG.

61 Conclusion: We show that in some adolescents, microbiome changes post-VSG may have
62 inflammatory potential, which may be of importance considering the increased incidence of
63 inflammatory bowel disease post-VSG.

64 **What is already known on this topic:** Bariatric surgery is highly effective in achieving weight
65 loss in children and adolescents with severe obesity, however the underlying mechanisms are
66 incompletely understood, and gut microbiome changes are unknown.

67 **What this study adds** – Significant gut microbiome and metabolome shifts were found several
68 months after vertical sleeve gastrectomy in adolescents, notably with enrichment of oral-associated
69 taxa. Using human to germ-free mice fecal transplant studies, the post-surgery changes in the gut
70 microbiome/metabolome were shown to have inflammatory potential. Furthermore, raised fecal
71 calprotectin and inflammatory systemic pathways were seen in a subset of adolescents post-
72 surgery.

73 **How this study might affect research, practice or policy** – These findings may be of importance
74 given the growing recognition of an increased incidence of inflammatory bowel disease after
75 bariatric surgery and warrants further investigation.

76

77

78

79

80

81 **Key words:** bariatric surgery, microbiota, metabolome; children, adolescents, pediatric,
82 inflammation, obesity, sleeve gastrectomy, childhood obesity, type 2 diabetes mellitus,
83 dyslipidemia

84

85 INTRODUCTION

86 The epidemic of childhood obesity continues unabated, with 19.3% of children and adolescents
87 having obesity and 6.1% having severe obesity in the USA¹. Multiple comorbidities are associated
88 with childhood obesity including type 2 diabetes mellitus (T2DM), metabolic dysfunction-
89 associated steatotic liver disease (MASLD), dyslipidemia, and continuation of obesity into
90 adulthood^{2,3}. If weight loss can be achieved prior to entering adulthood, the risk of these conditions
91 is mitigated. Therefore, childhood obesity is a key target for intervention⁴.

92 Bariatric surgery achieves significant weight loss and reduces or resolves associated comorbidities
93 in children with severe obesity⁵. Clinical guidelines recommend bariatric surgery as a potential
94 intervention for children and adolescents with class II obesity and comorbidities or class III obesity
95 with or without comorbidities^{6,7}. Laparoscopic vertical sleeve gastrectomy (VSG), with removal
96 of 80-90% of the greater curvature of the stomach, is the most common pediatric bariatric
97 procedure and the only type performed on those <13 years of age⁸.

98 Although VSG in children and adolescents is highly effective, the biological mechanisms
99 underlying the weight loss and metabolic improvement are not fully elucidated. Restriction of food
100 intake by reduction of stomach capacity plays an important role but the degree of enhanced
101 metabolism post-VSG cannot be explained by caloric restriction alone. VSG also leads to weight
102 loss through altered neurohormonal feedback mechanisms including increases in glucagon-like
103 peptide-1 (GLP-1) and peptide YY, which reduces appetite⁹.

104 There has been growing interest in the role of the gut microbiome in the mechanisms behind VSG.
105 Many studies have shown a difference in the gut microbiome between individuals with and without
106 obesity¹⁰. Moreover, murine models with fecal transplant (FT) from humans with obesity to germ-

107 free mice have shown transfer of the obesity phenotype indicating a causal role for the gut
108 microbiome¹¹. Studies examining gut microbiome changes after bariatric surgery in adults suggest
109 an increase in microbiota diversity and decrease in Firmicutes/Bacteroidetes ratio, although
110 specific changes differ between surgery type and amongst studies^{12 13}.

111 To our knowledge, the role of the gut microbiome in adolescents undergoing bariatric surgery has
112 not yet been examined¹⁴. This is uniquely important to study as the microbiome of children and
113 adolescents differs from adults¹⁵⁻¹⁷. The developing microbiome in childhood also plays a clear
114 role in establishing metabolic and inflammatory pathways that could impact energy regulation in
115 obesity^{18 19}. Additionally, there is mounting evidence suggesting that the age of onset of obesity
116 significantly impacts overall cardiometabolic risk, with childhood obesity possibly representing a
117 more virulent form of the disease as both MASLD and T2DM progress more rapidly in children
118 than adults²⁰⁻²². Thus, studying microbiome changes in children and adolescents may be of
119 particular importance. Furthermore, many of the studies in adults undergoing bariatric surgery
120 focused on Roux-en-Y gastric bypass, not VSG, used 16S rRNA gene microbiome sequencing,
121 and did not examine microbiome function and metabolites. Also, there are limited studies
122 examining whether the microbiota changes found with bariatric surgery have a causal role in the
123 beneficial phenotype changes seen post-surgery.

124 Therefore, we aimed to 1) deeply examine gut microbiome structure and function changes with
125 VSG in adolescents using shotgun metagenomic sequencing and wide metabolomic analysis and
126 2) assess if the microbiome/metabolome differences seen have a causal role in the phenotypic
127 changes observed with VSG by performing FT of stool from adolescents pre-VSG and post-VSG
128 into germ-free mice.

129

130 **RESULTS**

131 **Participants and clinical data**

132 Twelve participants provided paired stool samples within the 8 weeks (mean 2 weeks) prior to
133 VSG (pre-VSG) and follow-up stool samples 3-7 months (mean 5 months) after VSG (post-VSG).
134 The mean age at VSG was 15 years (range 10-18 years), 8/12 participants were female and 9/12
135 Black or African American (Table 1). Notably, 2 participants were identical twins.

136 At VSG, subjects had a mean body mass index (BMI) of 48.7kg/m² which decreased to 39.9 kg/m²
137 (p<0.0001) post-VSG (Table 1). Total body weight loss (TBWL) averaged 17.8% (range 5.9% -
138 32.9%). 8/12 participants had T2DM or prediabetes pre-VSG with a reduction to 0/12 post-VSG
139 (p=0.0078). 7/12 participants had elevated alanine aminotransferase (ALT) pre-VSG, indicating a
140 high likelihood of MASLD; only 1/12 participants had a liver biopsy which showed metabolic
141 dysfunction-associated steatohepatitis. Overall, mean ALT decreased from 28.2 U/L to 15.7U/L
142 (p=0.0025) with VSG. 4/12 participants had dyslipidemia with elevated low-density lipoprotein
143 (LDL) pre-VSG compared to 1/12 post-VSG, with an increase in high-density lipoprotein (HDL)
144 cholesterol post-VSG from an average of 41.3 mg/dL to 49.0 mg/dL (p=0.0317).

145 **Stool microbiome changes with VSG**

146 i. Alpha and beta diversity

147 Pre-VSG and post-VSG stool samples underwent shotgun metagenomic sequencing. Bacterial
148 diversity increased post-VSG (Shannon p=0.047, Inv Simpson p=0.04, Evenness (p=0.042)
149 Fig.1A). Significant changes in microbiome composition (beta diversity) were seen using the
150 Canberra distance, which places more weight on lower abundance species (p=0.015, Fig.1B) but
151 not Bray Curtis distance. Pre-VSG, alpha diversity was significantly lower in those with diabetes

152 compared with pre-diabetes and no diabetes (SuppFig.1A) and microbiome composition also
153 differed (SuppFig.1B). Post-VSG, there were no differences in alpha or beta diversity between
154 those who previously had diabetes and the other subjects. There were no significant differences
155 between changes in alpha and beta diversity and other clinical parameters.

156 ii. Taxonomic shifts

157 There was a significant enrichment of 76 bacterial taxa post-VSG. Notably, the top 18 species
158 enriched post-VSG were from the *Streptococcus* and *Actinomyces* genera (Fig.1C-1D. Supp Table
159 1). This included an enrichment of *Streptococcus salivarius*, *Streptococcus vestibularis*,
160 *Streptococcus parasanguinis*, *Actinomyces oris* and *Actinomyces oral taxon*, all of which are
161 commonly associated with the oral cavity. No individual taxa significantly correlated with clinical
162 characteristics.

163 iii. Carbohydrate-Active Enzymes (CAZymes)

164 CAZymes were examined due to their role in influencing host metabolism²³. While the overall
165 composition of CAZymes only showed a moderate change with VSG (Canberra PERMANOVA
166 $R^2 = 0.049$, $P=0.056$, Fig.2A), five specific CAZymes exhibited significant enrichment post-VSG
167 (Fig.2B, Supp Table 2). Many of the CAZyme enrichments post-VSG were associated with
168 *Streptococcus species* (Fig.2C). In addition, Glycoside Hydrolase 13 (GH13)+Carbohydrate
169 Binding Module 20 (CBM 20) significantly associated with increased TBWL ($q=0.002$, Supp
170 Table 2).

171 iv. Antibiotic resistance genes (ARGs)

172 ARGs were examined using the RGI CARD database. Four ARGs were enriched post-VSG: qacJ,
173 tetA(46), tetB(46) and vanY in vanF cluster (Fig.2D). These resistance genes, especially

174 tetAB(46), were primarily found in contigs belonging to several *Streptococcus* species enriched
175 post-VSG (Fig.2E).

176 v. Conserved functional enrichments

177 There were no functional pathway level differences with VSG. Therefore, reads were aligned to
178 Enzyme Commission (EC) gene annotations to identify more refined gene function differences.
179 There was a moderate change in lower-abundance genes post-VSG (Canberra $R^2=0.05$, $P=0.059$,
180 SuppFig.2A), most notably with enrichment of EC 1.1.1.105, an all-trans retinol dehydrogenase
181 gene, from the oxidoreductases class (SuppFig.2B, Supp Table 3). In addition, these enriched ECs
182 formed three distinct modules of co-associated genes (blue, brown and turquoise) that increased
183 significantly post-VSG (SuppFig.2C-D), driven by different bacterial genera (SuppFig.2E). ECs
184 in the blue module were primarily from mevalonate, hemiterpene biosynthesis and heme
185 biosynthesis pathways; those in the brown module focused on sugar acid degradation, and the
186 turquoise module contained several tRNA synthetases (Supp Table 3).

187 vi. Bacteriophage and viral composition

188 When looking at the DNA virome, there were no significant differences observed with VSG in
189 taxonomy, host taxonomy, taxonomic diversity, taxonomic composition, viral protein family
190 diversity or composition (SuppFig.3A-F). As most DNA viruses in the gut microbiome are phages,
191 this suggests phage-containing bacteria did not significantly change with VSG despite large overall
192 bacterial changes.

193 **Stool metabolome changes with VSG**

194 Post-VSG stool displayed higher ratios of secondary to primary bile acids compared to pre-VSG
195 stool (Fig.3A). Notably, this pattern was broad and included all ratios for which the corresponding
196 precursor primary bile acid and product secondary bile acid were detected.

197 Amongst polar metabolites, only the elevation of citrulline post-VSG passed a false discovery rate
198 cut-off of 10% (Fig.3B). However, several trends known to be important to gut health were
199 observed (Fig.3C). These included a decrease in acyl-carnitines, an increase in neurotransmitters
200 known to be directly microbially produced (GABA, dopamine, and histamine), and increases in
201 redox cofactor metabolites. No changes in SCFAs were observed.

202 Polar metabolites were related to a range of demographic and clinical factors (SuppFig.4, Supp
203 Table 4). Several amino acid metabolites (purple) positively associated with HDL, and negatively
204 associated with hemoglobin A1C (HbA1c) pre-VSG. In addition, several metabolites correlated
205 negatively with BMI pre-VSG, including those in Redox and Co-Enzyme metabolite (CoA, FMN,
206 NADH), Glycolysis (G1P, Glycerol-3P), and Nucleotide (UMP, AMP) classes. Post-VSG, several
207 metabolites associated with the degree of TBWL, including neurotransmitters such as GABA and
208 Dopamine, which also correlated negatively with triglyceride levels. Citrulline did not correlate
209 with any factors pre-VSG or post-VSG.

210 **Stool microbiome and metabolite correlations with VSG**

211 To reduce the dimensionality of the microbiota, taxa were agglomerated into seven co-associated
212 networks. Each increased in abundance post-VSG except for the red network, which exhibited a
213 trending decrease ($p=0.087$; SuppFig.5A-B, Supp Table 5). Changes in these networks were
214 correlated with changes in polar metabolites which revealed that the *Bacteroides* and the
215 *Alistipes/Akkermansia/Actinomyces* prominent group both increased in concert with several

216 SCFAs including butyrate, isovalerate, and isobutyrate (SuppFig.5C, Supp Table 5). Conversely,
217 the *Streptococcus* prominent group had the fewest correlations, only exhibiting positive
218 correlations with isocitrate and cytidine and a negative correlation with urate.

219 **FT into germ-free mice**

220 Next, to assess whether the microbiome/metabolome changes seen with VSG had a phenotypic
221 effect, germ-free mice were inoculated with pre-VSG or post-VSG stool from the same participant
222 (Fig.4A). Two human participants were chosen who had both pre-VSG and post-VSG stool stored
223 adequately in glycerol to preserve bacteria viability. Of note, one subject had the second-to-greatest
224 TBWL and the second had prediabetes pre-VSG which resolved post-VSG. Using 16S rRNA gene
225 sequencing, 6 weeks post-FT, mice transplanted with post-VSG stool had a higher alpha diversity
226 (Fig.4B) and different bacterial composition (PERMANOVA Bray Curtis $R^2 = 0.114$, $P=0.006$,
227 adjusted for human inoculum source, Fig.4C) compared to mice that received pre-VSG stool,
228 which was similar to the human stool microbiota findings. The mouse microbiome samples did
229 also show significant separation based on the human subject used as the inoculum (PERMANOVA
230 Bray Curtis $R^2=0.495$, $P=0.001$, adjusted for FT timepoint).

231 **Phenotype changes in germ-free mice**

232 Phenotypic differences resulting from FT with pre-VSG and post-VSG stools were compared. Six
233 weeks post-FT, there was no difference in body weight, food consumption, intraperitoneal glucose
234 tolerance tests, nor tissue weights (epididymal fat, subcutaneous fat and liver weights) between
235 mice that received pre-VSG versus post-VSG stool (Fig.4D-G respectively). Consistently, micro-
236 computed tomography revealed no differences in subcutaneous or intraabdominal adipose tissue
237 volume between the two groups (Fig.4H). There was a significant increase in serum resistin in

238 mice that received post-VSG stool compared to pre-VSG stool ($p=0.047$), but no differences in
239 other metabolic hormones (GLP-1, insulin, leptin, gastric inhibitory polypeptide, Fig.4I).

240 **Immune and inflammatory changes in germ-free mice**

241 Immune changes in the murine models were assessed in the large intestine lamina propria and
242 mesenteric lymph nodes using flow cytometry (SuppFig.6A). Of note, mesenteric lymph node data
243 was only available from one set of mice pre- and post-VSG FT. In the large intestine, there was a
244 significant decrease in $\gamma\delta$ T cells, a non-significant increase in $CD4^+$ T cells and decrease in $CD8^+$
245 T and NK cells in post-VSG mice (Supp.Fig6B). More importantly, there was a significant increase
246 in the number and proportion of Th17 cells, along with a significant decrease in $GATA3^+$
247 regulatory T cell (Treg) proportion in the large intestine and mesenteric lymph nodes of post-VSG
248 mice (Fig.5A, Supp.Fig6C) suggesting an inflammatory phenotype in the individuals studied.
249 Th17 cytokines (IL-17A and IL-22) were also increased in the mesenteric lymph node post-VSG
250 (SuppFig.6D) but did not reach significance in the colon. Sparse Partial Least Squares analysis of
251 the most discriminatory immune and metabolic readouts and microbial taxa showed a distinct
252 separation of pre- and post-VSG parameters indicating a direct or indirect association between the
253 microbiota and observed immune milieu. Notably, the increased Th17 phenotype observed in the
254 post-VSG mice clustered with increases in relative abundances of microbial taxa belonging to
255 Ruminococcaceae, Erysipelatoclostridaceae, and Monoglobus. Conversely, the increased Treg
256 populations in the pre-VSG mice were associated with increased levels of the taxa Parabacteroides
257 (SuppFig.6E).

258 **Inflammatory changes in humans with VSG**

259 Given the inflammatory phenotype post-VSG observed in the murine model, colonic inflammatory
260 changes were assessed in available human stool samples by fecal calprotectin (FC). 8/12
261 participants had stool frozen without preservatives to allow for FC assessment. 6/8 individuals had
262 an increase in FC to a clinically elevated level post-VSG ($>120\mu\text{g/g}$, Fig.5B). Of these 6
263 participants, the mean FC pre-VSG increased from $47\mu\text{g/g}$ to $497\mu\text{g/g}$ post-VSG ($p=0.0016$,
264 Fig.5B). 2/8 patients with an elevated FC level pre-VSG had a decrease post-VSG. There was no
265 correlation between length of time from surgery and FC levels. Subjects with raised FC post-VSG
266 did not report typical clinical symptoms associated with high levels such as diarrhea. Additionally,
267 the microbiome of subjects with increased FC also exhibited increased post-VSG microbiota
268 similarity compared to pre-VSG where samples were more distinct (p for interaction= 0.016 ,
269 Supplementary Fig.7A-B). No individual taxa correlated with FC increases.

270 To assess systemic immunity/inflammation changes with VSG, urine samples were utilized due to
271 the unavailability of blood samples. Proteomic analysis was performed using the SomaScan V4.1
272 Assay, where a subset of 1856 proteins were identified with detectable signals in urine from the
273 overall 7000 analyte panel that has been optimized for peripheral blood (SuppFig.8). When these
274 1856 proteins were compared between paired pre-VSG and post-VSG urine samples for 6 subjects,
275 no individual proteins differed significantly. However, 17 pathways exhibited significant positive
276 enrichment post-VSG ($\text{FDR}<0.05$, Fig.5C). The top enriched pathways included 4 pathways
277 involved in immune/inflammation regulation: IRAK2 mediated activation of TAK1 complex;
278 TICAM1, TRAF6-dependent induction of TAK1 complex; IRAK1 recruits IKK complex; and
279 IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation. Enrichment in all 4 pathways was
280 driven by the same set of 3 leading edge proteins related to ubiquitin, and the increased expression
281 observed post-VSG was conserved across participants with one exception (Fig.5C).

282 DISCUSSION

283 We comprehensively examined stool microbiome and metabolome changes pre- and post-VSG in
284 adolescents and assessed if these changes were causal in VSG-associated phenotypes using a
285 murine FT model. Our major findings were 1) increased microbiome diversity post-VSG, with
286 enrichment of several taxa, most notably in those usually associated with the oral cavity; 2)
287 increased ratios of secondary to primary bile acids post-VSG; 3) no differences in metabolic
288 phenotypes in germ-free mice transplanted with pre-VSG and post-VSG stool; 4) an inflammatory
289 phenotype in germ-free mice transplanted with post-VSG stool compared to pre-VSG stool defined
290 by an increase in $\gamma\delta$ T cells and Th17 cells and decrease in GATA3⁺ Tregs in the gut and a systemic
291 increase in resistin and 5) a corresponding inflammatory phenotype in a subset of adolescents post-
292 VSG with an increase in FC.

293 In our cohort, the gut microbiome increased in diversity and changed in composition with VSG.
294 Generally, an increase in alpha diversity is seen with all forms of bariatric surgery in adults, but
295 specific compositional and taxa changes vary by surgery type and study^{13 24}. In our study, there
296 was enrichment of taxa post-VSG, most notably in species commonly found in the oral cavity from
297 the *Streptococcus* and *Actinomyces* genera. Some other studies examining microbiome changes
298 post-VSG in adults have also seen an increase in these genera, although species could not be
299 accurately identified due to the use of 16S rRNA sequencing²⁵. This increase in oral-associated
300 taxa post-VSG is likely through a variety of mechanisms, including removing some of the physical
301 barrier with VSG that usually prevents the passage of oral taxa and also an increase in stomach pH
302 post-VSG²⁶. These changes are very likely due to VSG itself as they are rarely described in weight
303 loss alone²⁷. These changes may have potential microbial and immunological consequences.
304 Specifically, post-VSG within the enriched *Streptococcus* species, there was CAZyme enrichment

305 of GH13+CBM 20, a combination shown in fungi to enhance complex starch degradation²⁸.
306 Moreover, several ARGs enriched post-VSG were within the enriched *Streptococcus* species.
307 These findings collectively suggest that the *Streptococcus* species that become enriched in the gut
308 microbiome post-VSG are augmented for functions that may enhance their virulence. Overall, the
309 increase in oral-associated taxa may be clinically relevant as there has been increasing recognition
310 that enrichment of oral taxa in the gut maybe associated with several adverse inflammatory patient
311 outcomes, including inflammatory bowel disease (IBD) and subclinical coronary atherosclerosis²⁹⁻
312 ³¹.

313 There were significant changes in the stool metabolome and microbiome function post-VSG, many
314 of which are considered beneficial. There was a broad increase in the microbiota-driven conversion
315 of host-derived primary bile acids into secondary bile acids post-VSG, suggesting bolstering of
316 the host-to-microbiome communication cycle post-VSG³². Further, citrulline, which is understood
317 as both a marker of gut health and to have a role in obesity, was increased post-VSG ^{33 34}. This
318 molecule participates in the regulation of numerous pathways relevant to obesity and a therapeutic
319 effect of citrulline supplementation in the regulation of obesity associated metabolic imbalances
320 has also been suggested³⁵⁻³⁸ Moreover, microbially metabolized neurotransmitters including
321 GABA, dopamine, and histamine also trended upward post-VSG in support of a gut-neural
322 homeostasis improvement³⁹. Lastly, there was post-VSG enrichment of EC 1.1.1.105, an all-trans
323 retinol dehydrogenase gene, with Vitamin A signaling and homeostasis reported to play a role in
324 mitigating obesity⁴⁰. Overall, it is difficult to assess whether these potentially beneficial trends in
325 fecal metabolites are a result of VSG, post-VSG weight loss or both. The absence of SCFAs
326 changes post-VSG was notable, as changes have previously been reported in an adult study⁴¹.
327 Large inter-sample variance may have obscured trends in our cohort.

328 An assessment for a causal role of the microbiome/metabolome changes with VSG performed via
329 FT into germ-free mice did not identify favorable phenotypes such as decreased adiposity or
330 improved glucose tolerance in mice that received post-VSG stool. These findings contrast with
331 similar studies performing human to mouse FTs reporting improvements in body fat, glycemic
332 control and energy expenditure⁴²⁻⁴⁴ However, those studies involved stool samples from older
333 adults who were prediabetic or diabetic and employed mouse models that differed in age and sex
334 of mice, fecal inoculation, experimental timelines, and diet administered. We may not have seen
335 similar changes as the mice were harvested at 6 weeks following FT, which may not have been
336 long enough to allow phenotypic changes to develop, and only one of the human participants used
337 for FT had prediabetes pre-VSG.

338 An intriguing finding in our mouse model was the inflammatory phenotype in those receiving post-
339 VSG stools. Given that obesity is considered an inflammatory condition and subjects used for FT
340 experienced weight loss, decreased inflammation in mice receiving post-VSG FT was expected⁴⁵.
341 Indeed, a decrease in different measures of inflammation has been seen following both weight loss
342 of patients with obesity and in one report of decreased gut and systemic inflammation in adults
343 post-VSG^{46 47}. Conversely, we observed an increase in the systemic levels of resistin in post-VSG
344 mice, an adipokine increasingly being recognized as playing a role in inflammation^{48 49}. Moreover,
345 Th17 cells were increased and GATA3+ Tregs were decreased in the large intestine and mesenteric
346 lymph nodes of post-VSG mice. Numerous studies have described the role of Th17 and imbalance
347 of Th17/Treg ratio in inflammatory bowel disease^{50 51}. With relevance to VSG, one study of adults
348 undergoing VSG reported decreases in peripheral Tregs⁴⁷. Further, *Erysipelatoclostridiceae* that
349 positively correlated with Th17 in our study has been previously associated with inflammation in
350 mouse models^{52 53} In contrast, a recent study in mice demonstrated the beneficial role of

351 microbiota-induced Th17 in protection against diet-induced obesity and metabolic syndrome, a
352 finding not observed in our model⁵⁴. Collectively these data indicate that stool
353 microbiome/metabolome changes from VSG in humans may have gut and systemic inflammatory
354 potential when transplanted to germ-mice, although the underlying mechanisms remain to be
355 elucidated.

356 When inflammation was assessed in our pediatric participants, FC, a gut specific marker of
357 inflammation, was found to be raised in a subset of adolescents post-VSG, to levels well above the
358 normal reference range. Two studies in adults report persistently raised FC levels after bariatric
359 surgery, with one study showing a persistent increase above baseline 1-year post-VSG.^{55 56}
360 Interestingly in all studies including ours, raised FC levels did not correlate with adverse
361 gastrointestinal symptoms or TBWL. In our study, systemically, 4 pathways involved in
362 immune/inflammation regulation were enriched post-VSG, driven by proteins related to ubiquitin.
363 Ubiquitination of the IKK complex mediated via proteins IRAK and TRAF-6 is an important step
364 in the activation of the NF- κ B pathway that plays a critical role in the immune response to microbes
365 including the transcription of pro-inflammatory genes such as IL-2, IL-6, IL-12, TNF α , activation
366 of macrophages and differentiation of CD4⁺ T cells⁵⁷. Increased activation of this pathway has
367 been demonstrated as an important driver of IBD⁵⁸. Furthermore, the gut microbiota has been
368 shown to modulate the expression of this signaling cascade and thus directly influence gut
369 inflammation⁵⁹⁻⁶¹.

370 Elevated FC levels and enrichment of pathways related to pro-inflammatory responses in humans
371 post-VSG and an increased proportion of intestinal Th17 in comparison to Tregs, with increased
372 resistin levels in mice colonized with post-VSG microbiota, collectively suggest an inflammatory
373 state of subjects post-VSG. This may be clinically relevant given studies, including a large case

374 series and two national database studies, showing an increased incidence of IBD after bariatric
375 surgery⁶²⁻⁶⁴. One study reported an increased incidence of ulcerative colitis, but not Crohn's
376 disease, with VSG⁶³. It is widely accepted that IBD is at least in part a gut microbiome-mediated
377 disease in susceptible individuals⁶⁵. Therefore, we postulate that the large shifts in the gut
378 microbiome seen post-VSG can have inflammatory potential, and in certain individuals, this may
379 increase their risk of IBD or other inflammatory diseases. It could be argued that increases in FC
380 may be related to the actual VSG rather than gut microbiome changes resulting from VSG.
381 However, against this, is the inflammatory phenotype seen in mice transplanted with post-VSG
382 stool who did not receive surgery themselves and the level of FC post-VSG not correlating with
383 the length of time post-surgery.

384 Our findings by no means negate the many beneficial effects of VSG in adolescents with obesity.
385 However, they do highlight a new finding that microbiome changes post-VSG may be
386 inflammatory in some adolescents. This paves the way for further research to gain insight into
387 potential inflammatory mechanisms with gut microbiota changes post-VSG. Additionally, larger
388 studies of children and adolescents undergoing VSG followed for a longer period are needed to
389 assess whether microbiome changes and inflammation are persistent, and if those with persistent
390 inflammatory changes are at increased risk for adverse outcomes such as IBD.

391 Despite this being the first study to our knowledge to comprehensively examine microbiome and
392 metabolome changes post-VSG in adolescents and show that these changes with VSG can be
393 potentially inflammatory, the study has many limitations. The sample size is limited, partly due to
394 the limited number of adolescents undergoing VSG. Additionally, longitudinal samples after 7
395 months post-VSG were unavailable. While a large increase in oral-associated taxa was seen in the
396 stool post-VSG, no oral samples were available to confirm whether the same taxa from the oral

397 cavity were engrafting in the gut within a specific participant. Additionally, if these oral taxa
398 contribute to the inflammatory phenotype remains to be determined. Finally, a complete
399 assessment of inflammation in adolescents was limited as only stool and urine were available and
400 limited samples were available for the FT murine models to assess whether the findings held across
401 the participant cohort.

402 In conclusion, large changes in the stool microbiome and metabolome were seen in adolescents
403 post-VSG. There was a notable enrichment of oral-associated taxa in the gut post-VSG. The post-
404 VSG changes in the gut microbiome/metabolome were shown to have inflammatory potential
405 when transferred to a germ-free mouse model. Furthermore, raised FC and inflammatory systemic
406 pathways were seen in a subset of adolescents post-VSG. While VSG is highly effective for weight
407 loss and reduction of comorbidities in adolescents with obesity, we show the novel finding of
408 potential inflammatory microbiome changes post-VSG. This may be of importance given the
409 growing recognition of an increased incidence of IBD after bariatric surgery and warrants further
410 investigation.

411

412

413

414

415

416

417

418 **METHODS**

419 **EXPERIMENTAL MODEL AND SUBJECT DETAILS**

420 *HUMAN METHODS AND ANALYSIS*

421 **Subjects and samples**

422 Children and adolescents undergoing VSG between January 2021 to February 2023 were enrolled
423 in an Institutional Review Board (IRB) approved longitudinal cohort study “Biorepository of
424 Specimens for Pediatric Obesity Research Use” (Children’s National Hospital IRB protocol
425 #Pro00015976) with signed consent and assent (latter for those >11 years). Inclusion criteria were
426 children and adolescents (≤ 21 years) undergoing vertical sleeve gastrectomy at the Children’s
427 National Hospital in Washington DC. To be eligible for surgery, children 19 and under required a
428 BMI $\geq 120^{\text{th}}$ percentile of 95th percentile for age and sex with an obesity-related comorbidity
429 and/or BMI $\geq 140^{\text{th}}$ percentile.

430 Participants were enrolled up to 2 months prior to their planned VSG. After consent was obtained,
431 a stool and urine collection container were mailed to participants. For stool, participants mailed
432 back a sample aliquoted in an OMNIgene-gut tube and OMNImet-gut tube for DNA and
433 metabolite preservation respectively (DNA Genotek Inc)⁶⁶. Wherever possible participants also
434 returned whole stool aliquoted into tubes with glycerol (for bacterial preservation) and whole stool
435 without preservatives. Participants gave a clean catch urine sample mixed with AssayAssure ®
436 Genelock (Sierra Molecular) for protein preservation. All samples were mailed back overnight on
437 icepacks and stored at -80°C until analysis. The same procedure was followed for post-VSG
438 samples. Clinical data was obtained via extraction of medical records from clinical appointments
439 pre-VSG and post-VSG and patient collected data accompanying the samples and was stored in a

440 secure REDCap database. For clinical data analysis, BMI, weight, HbA1c%, LDL, HDL,
441 triglycerides, and ALT passed Shapiro-Wilks normality and were compared pre-VSG and post-
442 VSG via paired t-tests. T2DM, dyslipidemia, and hypertension were compared via McNemar exact
443 tests.

444 **Patient involvement**

445 Patients were involved in the design and conduct of the trial. We received input from patients in
446 prior trials for the design of convenient sample collection methods that would minimize
447 inconvenience and were suitable for the planned downstream assays. We intend to disseminate the
448 main results to study participants.

449 **Microbiome sequencing**

450 *DNA Extraction:* DNA was extracted from human and murine fecal samples in two stages. First,
451 approximately 50 mg of fecal material and 650 μ L MBL lysis buffer from the PowerMicrobiome
452 DNA/RNA EP Kit (Qiagen) were added to Lysis Matrix E (LME) tubes (MP Biomedicals). LME
453 tubes were transferred to a Precelleys 24 Tissue Homogenizer (Bertin Technologies) and fecal
454 samples were homogenized, centrifuged, with the resultant supernatant transferred to a deep-well
455 96-well plate. The second stage consisted of DNA isolation from the above supernatant using the
456 MagAttract PowerMicrobiome DNA/RNA EP Kit (Qiagen) on an automated liquid handling
457 system as detailed by the manufacturer (Eppendorf).

458 *Shotgun Metagenomic Sequencing:* Total gene content of the microbiome was assessed through
459 shotgun metagenomic sequencing. Metagenomic libraries were constructed from 100 ng of DNA
460 as starting material using the Illumina DNA Prep kit. Illumina DNA/RNA UD Indexes were used
461 to add sample-specific sequencing indices to both ends of the libraries. An Agilent 4200

462 TapeStation system with High Sensitivity D5000 ScreenTape (Agilent Technologies, Inc) was used
463 to verify quality and assess final library size. A positive control (MSA-2002 20 Strain Even Mix
464 Whole Cell Material (ATCC)) and a buffer extraction negative control were included.
465 Metagenomic libraries were normalized and pooled at an equimolar concentration. Final pools
466 were diluted to 750 pM and sequenced on a NextSeq2000 sequencer using a paired-end (100x100)
467 NextSeq 1000/2000 P2 (200 cycles) kit (Illumina, Inc).

468 **Microbiome analysis**

469 *Data Processing:* The quality of raw paired-end sequence reads was assessed with FastQC⁶⁷ and
470 MutiQC⁶⁸. Adapters revealed by FastQC were removed using bbtools' bbdduk software. Reads then
471 underwent the Whole Genome Sequence Assembly 2 (WGSA2)⁶⁹ protocol using the Nephele
472 platform⁷⁰ (version 2.24.2). In brief, reads were processed with fastp⁷¹ and minimal trimming and
473 filtering by ensuring an average read quality of 10, a trim of the 3' end of the read at a quality of
474 15 and trimming of the 5' end at a Q score of 20, with additional filtering of reads if they were less
475 than 60 bases after trimming. Decontamination was undertaken using Kraken2⁷² with a database
476 containing the human and mouse genome. After adapter trimming and filtering, samples contained
477 between 15M and 30M paired-end reads, of which between 8.7M and 22M were classified to the
478 bacterial kingdom. Taxonomic identification was performed on the trimmed, error-corrected, and
479 decontaminated reads in Kraken2 with the default RefSeq database.

480 *Assembly and Gene Annotation:* Within the WGSA2 pipeline, the trimmed, error-corrected and
481 decontaminated reads were assembled into contiguous sequences, or contigs, using metaSPAdes⁷³.
482 Reads were recruited back to contigs using bowtie2⁹ and SAMtools⁷⁴ to produce information on
483 scaffold coverage and quality. Protein coding regions (CDS) were predicted from assembled
484 scaffolds using prodigal. Predicted CDS regions were processed by EggNog-mapper2⁷⁵ to identify

485 and annotate genes with KEGG Orthology (KO), Enzyme Commission (EC) and Clusters of
486 Orthologous Genes (COG) identifiers. Abundances were calculated using *verse*⁷⁶ to obtain
487 Transcripts Per Million (TPM) at the CDS level and summed to obtain TPM by gene.

488 *CAZymes*: Carbohydrate Active Enzymes (CAZymes) were annotated from assembled
489 metagenomic scaffolds using the dbCAN software⁷⁷ in meta mode with default settings and default
490 databases to obtain eCAMI, HMMER and DIAMOND-based annotations. Annotations were
491 provided at the gene level and merged with predicted gene abundances. Genes were also annotated
492 with taxonomy using Kraken2, creating a table of CAZyme abundances both stratified by
493 taxonomy and unstratified. Gene abundances were normalized to copies per million before
494 analysis. The eCAMI-based CAZyme identification was used in analysis and focused specifically
495 on CAZymes supported by DIAMOND or HMMER when available.

496 *Antibiotic Resistance Genes*: Antibiotic resistance genes were identified using the Comprehensive
497 Antibiotic Resistance Database with the Resistance Gene Identifier tool v6.0.1, nudging loose hits
498 to strict and including low quality assemblies with prediction of partial genes (ref). Resulting
499 annotations were processed as for CAZymes.

500 *Virome*: After assembly with WGS2, assembled scaffolds and binary alignment maps (BAM)
501 were processed for the presence of viral diversity (ssDNA, dsDNA phage, and giant DNA viruses)
502 using Nephele's DiscoVir pipeline (https://nephele.niaid.nih.gov/pipeline_details/discovir/).
503 Briefly, geNomad predicted viral genomes and fragments using default confidence parameters as
504 defined by the tool, and VERSE calculated read counts of viral genomes based on BAM files^{78 79}.
505 Next, CheckV assessed quality and all scaffolds identified as viral were retained for downstream
506 processing and analysis⁸⁰. Viral genomes and fragments greater than 1000 basepairs were clustered
507 with bbtools and MMseqs2 to generate vOTUs which were functionally annotated with DRAM-

508 v with KOfam, Pfam, and Viral Orthologous Group (VOG) databases. Auxillary metabolic genes
509 were identified with VirSorter2.0 and DRAM-v⁸¹⁻⁸³. Phage hosts were predicted using iPHoP⁸⁴.

510 *Statistical Analysis:* All statistical analysis of the microbiome was performed using R 4.3.0. For
511 taxonomic analysis, reads were filtered to those that aligned to the bacterial kingdom and
512 normalized with rarefaction to 8 million reads per sample. Several measures of alpha diversity
513 were calculated, including Chao1 Richness, Observed Taxa, Evenness, Inverse Simpson, and
514 Shannon Diversity using `estimate_richness` from `phyloseq`⁸⁵. For all data types, Bray Curtis and
515 Canberra distance matrices were calculated using `phyloseq`'s distance function. Alpha diversity
516 was compared between pre-VSG and post-VSG samples using linear mixed-effects models within
517 the `lmerTest` package⁸⁶. The composition of the microbiome was compared against study
518 covariates with Permutational Analysis of Variance (PERMANOVA) using the `adonis2` function
519 from the `vegan` package⁸⁷. Significant relationships were visualized using Principal Coordinates
520 Analysis (PCoA) ordination in `phyloseq` and `ggplot2`⁸⁸. All differential abundance analyses were
521 undertaken with `Maaslin2`⁸⁹, wherein data was analyzed with linear models after log-
522 transformation. Features were filtered if they exhibited a minimum prevalence of less than 10%
523 and a minimum variance of 0.01. When paired samples were included, Subject ID was provided
524 as a random effect. An FDR-corrected p-value less than 0.2 was considered significant.

525 Co-associated networks of taxa or EC abundances were generated using Weighted Gene Co-
526 Association Network Analysis⁹⁰. In brief, this tool reduces multi-dimensional data to co-associated
527 networks or modules. For taxa-based modules, taxa were included that were found to change
528 nominally after surgery at a false-discovery-corrected p-value of less than 0.5. Blockwise modules
529 were generated using a soft power threshold of 14, an unsigned topology overlap matrix, minimum
530 module size of 20, merge cut height of 0.15, and `deepSplit` of 3. This process generated eight

531 modules of taxa that were annotated manually by combining the taxonomic information, the
532 average abundance of the taxon across samples, and the module membership, calculated as the
533 correlation of the taxon abundance with the module eigengene.

534 WGCNA modules were also created for EC abundances using similar settings. ECs were included
535 if they changed significantly due to surgery at an FDR P-value of 0.4. Modules were constructed
536 using the same parameters as above except with a soft power threshold of 7. This resulted in four
537 distinct modules of ECs. These were described using the pathway enrichment tool OmePath⁹¹,
538 where scores used were based on module membership and calculated as described previously.

539 Relationships between module eigengenes and metabolites were identified using linear mixed
540 effects models. Results were visualized using the igraph package²¹ if they were significant at an
541 FDR p-value less than 0.05. Directionality of the results was represented by edge color and data
542 type was indicated through color of nodes.

543 This work utilized the computational resources of the NIH HPC Biowulf cluster
544 (<http://hpc.nih.gov>) and the NIAID Locus cluster (<http://locus.niaid.nih.gov>).

545 **Metabolomics**

546 *Metabolite and Lipid Sample Preparation:* For all liquid chromatography mass spectrometry
547 (LCMS) methods, LCMS-grade solvents were used. For bile acid analysis 400 μ L of homogenized
548 feces was taken from the fecal collection tubes and added to 500 μ L of ice-cold methanol. To each
549 sample 5 μ L of the Bile Acid SPLASH® (Avanti Polar Lipids Inc.) and 2 μ g of butylated
550 hydroxytoluene was added. Samples were agitated via shaking at 4°C for 20 minutes and then
551 centrifuged at 16k xg for 20 min. An aliquot of the supernatant was taken directly for liquid LCMS
552 analysis.

553 For short-chain fatty acid (SCFA) and polar metabolomics, a separate 400 μ L aliquot of
554 homogenized feces was added to 400 μ L of water. Following mixing, 400 μ L of chloroform was
555 added. Samples were shaken for 30 minutes at 4°C and subsequently centrifuged at 16k xg for 20
556 min. 400 μ L of the top (aqueous) layer was collected. The aqueous layer was sub-aliquoted for
557 SCFA derivatization or diluted 5x in 50% methanol in water and prepared for LCMS injection.

558 *SCFA Derivatization:* To preserve SCFAs for analysis an aliquot of the aqueous fraction was
559 derivatized with O-benzylhydroxylamine (O-BHA) as previously described with modifications⁹²
560 ⁹³. The reaction buffer contained 1M pyridine and 0.5 M hydrochloric acid in water. To 35 μ L of
561 sample, 10 μ L of 1M O-BHA in reaction buffer and 10 μ L of 1M 1-Ethyl-3-(3-
562 dimethylaminopropyl) carbodiimide in reaction buffer were added. Samples were derivatized for
563 2 hours at room temperature with constant agitation. Addition of 50 μ L of 0.1 % formic acid was
564 used to quench the reaction, which eliminated the potential for formate to be measured in these
565 samples. To extract derivatized molecules 400 μ L of ethyl acetate was added. The samples were
566 centrifuged at 16k xg and 4°C for 5 min to induce layering. The upper (organic) layer was collected
567 and dried under vacuum. Samples were resuspended in 300 μ L of water for LCMS injection.

568 *Liquid Chromatography Mass Spectrometry:* Tributylamine and all synthetic molecular references
569 were purchased from Millipore Sigma. LCMS grade water, methanol, isopropanol and acetic acid
570 were purchased through Fisher Scientific.

571 All samples were separated using a Sciex ExionLC™ AC system and measured using a Sciex 5500
572 QTRAP® or Sciex 6500+ QTRAP® mass spectrometer.

573 Polar metabolites were analyzed as previously described⁹⁴. For all metabolomics analysis, quality
574 control samples, consisting of a mixture of the analyzed samples, were injected after every 10

575 injections to control for signal stability. Samples were analyzed via separate negative ionization
576 and positive ionization methods. For negative mode analysis, a Waters Atlantis T3 column (100 Å,
577 3 μm, 3 mm × 100 mm) with a gradient from 5 mM tributylamine, 5 mM acetic acid in 2%
578 isopropanol, 5% methanol, 93% water (v/v) to 100% isopropanol over 15 min was used. For
579 positive mode analysis, samples were separated on a Phenomenex Kinetex F5 column (100 Å, 2.6
580 μm, 2.1 mm × 100 mm) column with a gradient from 100% water with 0.1% formic acid to 95%
581 acetonitrile with 0.1% formic acid over 5 min. Each metabolite was measured using at two distinct
582 multiple reaction monitoring (MRM) signals and a defined retention time.

583 For SCFA analysis samples were separated on a Waters™ Atlantis dC18 column (100Å, 3 μm, 3
584 mm X 100 mm) with a 6 min gradient from 5-80 % B with buffer A as 0.1 % formic acid in water
585 and B as 0.1 % formic acid in methanol. All SCFA were measured using positive ionization using
586 MRMs that featured the characteristic 91 daughter ion from O-BHA derivatization. Identity was
587 confirmed via comparison to previous standards.

588 Bile acid samples were separated on a Phenomenex Kinetex® Polar C18 (100Å, 2.6 μm, 3 mm X
589 100 mm) using a binary gradient of A: 0.01 % acetic acid in water and B: 0.01 % acetic acid in
590 methanol. A 20 min gradient from 40-100 % B was utilized for separation. Samples were detected
591 in negative MRM mode using previously validated MRMs⁹⁵. Internal bile acid standard signals
592 were used to confirm signal identities and retention times.

593 *Metabolomic analysis:* All signals were integrated using SciexOS 3.1 (AB Sciex Pte. Ltd.). Signals
594 with greater than 50% missing values were discarded and the remaining missing values were
595 replaced with the lowest registered signal value. All signals with a QC coefficient of variance
596 greater than 30% were discarded. Metabolites with multiple MRMs were quantified with the
597 higher signal-to-noise MRM. Filtered datasets were total sum normalized prior to analysis. The

598 SCFA dataset and the two polar metabolomics datasets were scaled and combined using common
599 signal for serine and succinate for the positive mode metabolite method and the SCFA method
600 respectively. A paired t-test was used for all bile acid and metabolite statistics and a Benjamini-
601 Hochberg method for correction for multiple comparisons was imposed where indicated.

602 **Fecal Calprotectin (FC)**

603 FC was assessed using the Buhlmann Fecal Calprotectin ELISA kit (BÜHLMANN fCAL®
604 ELISA, <https://buhlmannlabs.com/buhlmann-fcal-elisa/>) following the manufacturer's guidelines.
605 The FCs included all subjects who did not pass Shapiro-Wilks normality, so pre- and post-VSG
606 were compared via a Wilcoxon test. FCs excluding outliers passed normality and were compared
607 pre- and post-VSG via a paired t-test.

608 **Urine Proteomics**

609 Urine samples were analyzed using the SomaScan V4.1 Assay, an aptamer-based quantitative
610 proteomic biomarker discovery platform (SomaLogic; Boulder, CO). The assay was run according
611 to manufacturer specifications which includes pH adjustment and buffer exchange by gel filtration
612 prior to normalizing total protein concentration of urine samples to a standard input concentration
613 ([https://somalogic.com/wp-content/uploads/2023/09/D0005009_Rev1_2023-09_SomaScan-7K-
614 v4.1-UrinePre-processing-User-Manual.pdf](https://somalogic.com/wp-content/uploads/2023/09/D0005009_Rev1_2023-09_SomaScan-7K-v4.1-UrinePre-processing-User-Manual.pdf)). Data was then subjected to the manufacturer's
615 standard normalization methods, including adaptive normalization by maximum likelihood by
616 SomaLogic.

617 Identified enriched gene sets were determined utilizing the pre-ranked gene-set enrichment
618 analysis (GSEA) algorithm, as implemented in the FGSEA R package⁹⁶. Genes were prioritized
619 based on moderated T statistics derived from the limma model's relevant coefficient, and

620 enrichment analysis was conducted using the Reactome database, with correction of p values
621 applied for multiple sampling. This analysis can be used to identify significant enrichment of a set
622 of foreground genes or proteins, in predefined gene sets, compared against a reference set. Quality
623 control and initial data processing were performed using an R package
624 (<https://github.com/foocheung/sqs>) and Shiny app⁹⁷.

625 ***MOUSE METHODS AND ANALYSIS***

626 **Mice and FT**

627 Germ-free C57BL/6NTac were bred and maintained at the NCI or NIAID Gnotobiotic animal
628 facility. Mice were screened by microbiological culture and 16S rRNA PCR to ensure their germ-
629 free status. Mice were fed a standard irradiated 5KAI diet (LabDiet). Pre-VSG and post-VSG
630 fecal samples from two human subjects stored in 20% glycerol at -80°C were used for fecal
631 microbiota transplant (FMT) into 5-6 week old male mice. Each mouse was orally inoculated with
632 200 µl of 35-60 mg stool slurry resuspended in sterile pre-reduced PBS in the anaerobic chamber.
633 Stool suspension was stored in a hungate tube. Each mouse was housed in a separate cage in
634 biocontainment racks in the same facility following inoculation. Body weights and feed
635 consumption was measured weekly and stool samples were collected for sequencing. Experiments
636 were performed independently for each human subject and 4-6 mice were inoculated with either
637 pre-VSG or post-VSG stool samples for each subject. All procedures were performed in
638 accordance with approved animal study proposals by NCI or NIAID Animal Care and Use
639 Committees.

640 **Glucose tolerance test**

641 Mice were fasted overnight for 12-14 hours. Glucose (2g/kg body weight) was administered
642 intraperitoneally, and glucose measurements were performed via tail bleeds using a glucometer
643 (DSS Precision Xtra) before and at 15, 30, 60, 90, and 120 mins after glucose administration.

644 **Micro-computed tomography (Micro-CT)**

645 QuantumGX scanner was used to obtain in-vivo high-resolution micro-CT imaging. Mice were
646 anesthetized using 2.5% isoflurane, eyes protected with Artificial Tears ointment and transferred
647 onto the imaging bed and maintained on 2% isoflurane during the imaging process. Images were
648 obtained in 3 slices at 70 mm magnification and reconstructed. Adipose tissue for each mouse was
649 quantified and analyzed using Analyze14 software. Intra-abdominal and subcutaneous fat were
650 isolated using a threshold range of approximately -300 to -50 Hounsfield units.

651 **Tissue harvest and isolation of cells from large intestine and mesenteric lymph nodes**

652 Immediately after micro-CT imaging animals were euthanized with CO₂ and blood was collected
653 by cardiac exsanguination. Subcutaneous fat from the abdominal region, epididymal fat pads, and
654 liver were harvested and weighed. Mesenteric lymph nodes were harvested and cells were isolated
655 by passing through a 70- μ m cell strainer, centrifuged at 1500 rpm for 5 mins for flow cytometry
656 analysis. Large intestines (LI, cecum and colon) were collected and placed on ice-cold complete
657 media (RPMI 1640 supplemented with 20mM HEPES, 2mM L-glutamine, 1mM sodium pyruvate,
658 1mM nonessential amino acids, 50 mM β -mercaptoethanol, 100U/ml penicillin and 100 mg/ml
659 streptomycin) + 3% fetal bovine serum (FBS). The tissue was then opened longitudinally, fecal
660 contents removed and cut into 1-2 cm pieces, and incubated in 20 ml of complete media + 3% FBS
661 + 5mM EDTA + 0.145 mg/ml DL-dithiothreitol for 20 mins at 37°C and 5% CO₂ with shaking. To
662 remove epithelial cells, LI were strained and vigorously shaken in a 50 ml tube containing 10 ml

663 complete media + 2mM EDTA, thrice. LI were then finely chopped and digested with 10 ml of
664 digestion media (complete media + 0.1 mg/ml Liberase TL, Roche + 0.05% DNase I, Sigma) for
665 25 mins at 37°C and 5% CO² with shaking. The digestion was stopped by adding 10 ml complete
666 media + 3% FBS. Digested tissues were then passed through 100-µm cell strainers, centrifuged at
667 1500 rpm for 5 mins, followed by straining through 40-µm cell strainers and centrifugation at 1500
668 rpm for 5 mins. Isolated lamina propria cells were then resuspended in complete media + 10%
669 FBS for flow cytometry analysis.

670 **Spectral flow cytometry**

671 Isolated single-cell suspensions were assessed for cytokine production potential by stimulation
672 with Cell Stimulation cocktail 500X (Thermo Fisher Scientific) prepared in complete media + 10%
673 FBS for 2.5 hours at 37°C. To assess lymphoid cells, cells were incubated with Zombie NIR
674 Fixable Viability Dye for 15 mins at room temperature. Cells were then washed and incubated with
675 a cocktail of fluorescently labeled antibodies prepared in PBS + 1% FBS +10% Brilliant Stain
676 Buffer + 10% TruStain FcX for 25 mins in the dark at 4°C: anti-CD45, anti-TCRβ, anti-CD44,
677 anti-CD90.2, anti-CD8β, anti-CD4, anti-TCRγδ and anti-NK1.1. Cells were then
678 fixed/permeabilized in eBioscience FoxP3 Fixation/Permeabilization Solution kit overnight at 4°C
679 and stained with a cocktail of fluorescently labelled antibodies against intracellular antigens
680 prepared in eBioscience intracellular staining buffer: anti-FoxP3, anti-GATA3, anti-RORγt, anti-
681 Tbet, anti-IFNγ, anti-IL17A and anti-IL22.

682 All samples were collected on an Aurora spectral cytometer (Cytex). Spectral unmixing was
683 performed using single-control controls using cells from corresponding tissues or UltraComp
684 eBeads (Invitrogen) and data were analyzed using FlowJo version 10.

685 **Serum metabolic hormones measurement**

686 Mouse serum concentrations of metabolic hormones were assessed using the Hormone Exp Panel
687 kit (Millipore, MMHE-44K-06) according to the manufacturer's protocol and measured using
688 Luminex MAGPIX Instrument (Bio-Rad). Data were analyzed using GraphPad Prism9.0 (Graph
689 Pad software, La Jolla, CA, USA) with unpaired t-tests. Differences were considered to be
690 statistically significant when $p < 0.05$.

691 **Microbiome sequencing:16S ribosomal RNA Gene Sequencing**

692 DNA extraction was as per human samples. Microbiome composition was assessed via dual-index
693 amplification of the V4 region of the 16S ribosomal RNA gene (16S rRNA). This method used the
694 V4 16S rRNA 515F and 806R primers with individual sample-specific indices and Illumina
695 sequencing adapters appended as previously described⁹⁸. The V4 region was amplified using: 5
696 μM of F/R primers, 1X Phusion High-Fidelity DNA Polymerase (New England Biolabs) and 100
697 ng of DNA as starting material. PCR conditions for amplification were as follows: initial template
698 denaturation at 98°C for 60s; 25 cycles of denaturation at 98°C for 10s, primer annealing 55°C for
699 30s, and template extension at 72°C 60s; with a final template extension at 72°C for 5 min. AMPure
700 XP beads (Beckman-Coulter) at a 1:1 ratio with the above PCR reaction were used to isolate final
701 PCR products.

702 Final 16S rRNA V4 libraries were quantified using the KAPA qPCR Library Quantification Kit
703 (Kapa Biosystems) and pooled at an equimolar concentration. Pools were normalized to 8 pM,
704 spiked-in with 15% phiX control library (Illumina) to add sequence diversity, and sequenced on
705 the Illumina MiSeq instrument utilizing the 600 cycle Paired-End (250x250) Reagent Plate with
706 the addition of 16S V4 rRNA specific sequencing primers⁹⁸.

707 **Microbiome analysis**

708 Samples collected from the murine study at six weeks as well as the human inoculum (pre-VSG
709 and post-VSG samples from two subjects) underwent 16S rRNA sequencing on the Illumina
710 MiSeq. The resulting sequences were reviewed for quality using FastQC and multiQC through
711 Nephele's microbiome analysis platform. Sequences were trimmed to 210 bases on the forward
712 reads and 180 bases on the reverse read, and those with a maximum expected error greater than
713 two were filtered out, reads then underwent Divisive Amplicon Denoising Algorithm 2 (DADA2)
714 utilizing Nephele's microbiome analysis platform⁹⁹. After the identification of sequence variants
715 through denoising, they were checked for chimeras and assigned taxonomy up to the species level
716 using the SILVA database. If a sequence variant aligned to multiple species with 100% identity, all
717 species were listed. Once reads were agglomerated into a table of counts, reads from negative
718 controls were subtracted from samples to be conservative about potential sources of contamination.

719 The sequence variant table was rarefied to 70,000 reads per sample after reviewing rarefaction
720 curves and sequences available per sample. Alpha diversity metrics, including Chao1 richness,
721 Evenness, Inverse Simpson and Shannon diversity values, as well as a Bray Curtis distance matrix,
722 were calculated using phyloseq. Linear models determined differences in alpha diversity, and
723 vegan's PERMANOVA utilizing marginal adjustment for the subject that served as the inoculum
724 source identified differences in community composition between the gut microbiome of pre-VSG
725 and post-VSG mice.

726 **Multi-Omic analysis**

727 DIABLO from the mixOmics package implemented sparse Partial Least Squares (sPLS) to
728 perform discriminant analysis of multi-omic data¹⁰⁰. Extensive k-fold cross validation and leave-

729 one-out analysis was performed but did not provide stable estimates to obtain an optimal number
730 of features. Therefore, the top 10 most discriminant features from each data type and human
731 inoculum sources that differentiated pre-VSG mice from post-VSG mice were selected for
732 inclusion in the combined visualization of microbiota and flow data sources.

733

734

735

736

737

738

739

740

741

742

743

744

745

746

747

748 **FIGURE LEGENDS**

749 **Fig.1. Microbial taxa exhibit significant changes after VSG.** (A) Subjects exhibited increases
750 in several alpha diversity metrics post-VSG (LME P-value < 0.05). (B) Significant changes in
751 underlying microbiota were also observed (Canberra PERMANOVA $R^2 = 0.06$, $P=0.015$). (C) Taxa
752 enriched post-VSG included several members of the *Streptococcus* and *Actinomyces* genera (FDR
753 $P < 0.05$). (D) All taxa at a species level that significantly increased post-VSG in order of
754 coefficient. Abbreviations: VSG: vertical sleeve gastrectomy, FDR: False Discovery Rate, LME:
755 Linear Mixed Effects; PERMANOVA: Permutational Analysis of Variance.

756 **Fig.2. Carbohydrate-Active Enzymes (CAZymes) and Antibiotic Resistance Genes (ARGs)**
757 **identified from metagenomic data exhibit increases in *Streptococcus* species after VSG.** (A)
758 Composition of CAZymes shows moderate change (Canberra PERMANOVA $R^2 = 0.049$,
759 $P=0.056$). (B) Interrogating specific CAZymes, five exhibited significant enrichments post-VSG
760 (MaAsLin2, FDR $P < 0.25$). (C) Heatmap shows significant CAZyme genes from panel B,
761 stratified by gene-based taxonomy. (D) Antibiotic Resistance Genes enriched ($P_{fdr} < 0.1$) after
762 surgery. (E) Antibiotic resistance genes with the largest effect size, *tetA*(46) and *tetB*(46) identified
763 primarily in *Streptococcus* contiguous sequences. Abbreviations: VSG: vertical sleeve
764 gastrectomy, CBM: Carbohydrate Binding Module, CPM: Copies Per Million, GH: Glycoside
765 Hydrolase, PERMANOVA: Permutational Analysis of Variance.

766 **Fig.3. Stool metabolite changes with VSG.** (A) Bile acid levels assessed by LC-MS/MS and the
767 conversion ratios were calculated to reflect known primary to secondary bile acid, and
768 unconjugated to conjugated bile acid substrate/product pairs. Ratios post- vs. pre-VSG were
769 analyzed by a paired t-test and the fold change and significance of the change are reflected as the
770 color of each node and the size of each node by row respectively in the displayed heatmap. All

771 measured ratios are displayed. (B) Polar fecal metabolites were assessed by LC-MS/MS and total
772 sum normalized prior to analysis. Paired fold changes of post- vs pre-VSG and significance by
773 paired t-test are displayed with a false discovery rate of 10 % indicated at $p=0.0012$, calculated via
774 a Benjamini-Hochberg correction. Pathways and molecular families of interest are indicated via
775 color. (C) A heatmap of the paired post- vs. pre-VSG changes displayed in (B) broken out by
776 participant to display variance and observed pathway-driven trends in metabolite levels. All
777 displayed features have a raw $p<0.1$ via a paired t-test. Abbreviations: LC-MS/MS: Liquid
778 Chromatography Mass Spectrometry, VSG: vertical sleeve gastrectomy, Acyl-Carn: acyl-
779 carnitines, Neuro: neurotransmitters, Nucleic: nucleic acids, nucleosides, and nucleotides, Org.
780 Acids: organic acids, SCFA: short-chain fatty acids

781 **Fig.4. Fecal transplant with pre-VSG and post-VSG stool into germ-free mice.** (A) Schematic
782 of experimental design. Pre-VSG and post-VSG stool samples were inoculated (FT) into two
783 groups of germ-free mice ($n=4-6$ /group). Body weights and feed consumption were measured
784 every week and mouse stool samples collected at 6 weeks were sequenced and analyzed. At week
785 6 following FT, a glucose tolerance test was performed. Following micro-CT imaging, mice were
786 sacrificed for sample collection. The experiment was repeated using samples from two
787 participants. (B) Alpha diversity was higher among mice receiving post-VSG stool, compared to
788 those receiving pre-VSG stool. (C) Mice also exhibited compositional differences between pre-
789 VSG and post-VSG stool, which was distinct from inoculum samples. (D) Weight change in mice
790 following FMT with pre-VSG and post-VSG stool is shown as a percentage of starting weight. No
791 significant differences were found. (E) No differences in feed consumption between the two groups
792 were found. (F) Glucose tolerance tests showed blood glucose levels at different time points of the
793 test (left) and the area under the curve for the entire test is plotted (right) for the two groups. The

794 two participants are identified as shown in the key. (G) Weight measurements for epididymal and
795 subcutaneous fat pads and liver tissues are plotted for the two groups. (H) Micro-CT results
796 showing adipose areas examined in the mouse (top left), total adipose tissue volume (top right),
797 subcutaneous adipose tissue volume (bottom left), and intraabdominal adipose tissue volume
798 (bottom right). No differences were seen between groups. (I) Serum metabolic hormone
799 measurements. Resistin was higher following FT with post-VSG stool compared with pre-VSG
800 stool; no other differences were seen. Abbreviations: VSG: vertical sleeve gastrectomy, FT: fecal
801 transplant.

802 **Fig.5. Immune and inflammation assessment in mice and humans.** (A) Representative contour
803 plots depicting ROR γ t⁺ and GATA3⁺ Treg populations and Th1 and Th17 populations from the
804 lamina propria cells of the large intestine (left). Gating strategy is shown in SuppFig.6A. The
805 number of live cells for each of the CD4⁺ T cell subsets and their proportion are plotted (right).
806 Data are based on FMT from 2 participants as shown in the key and are displayed as mean \pm
807 standard error of the mean. Statistical significance between the pre-VSG and post-VSG groups
808 was calculated using an unpaired Student's t-test and non-significance (ns) or p-values are
809 indicated. (B) Fecal calprotectin levels in all human subjects who had paired stool samples
810 available (n=8, top) and all subjects who had an increase in calprotectin with VSG (n=6, bottom).
811 (C) Urine proteomic pathways significantly enriched post-VSG. 1856 proteins quantified in urine
812 were compared between timepoints before and after VSG for 6 subjects and ranked by t-statistic
813 for enrichment analysis using Reactome gene sets. All pathways significantly positively enriched
814 for an increase in change post-VSG are shown (FDR adjusted $p < 0.05$), with enrichment score
815 and significance indicated by plotted color and size (left). For 4 pathways of interest, expression
816 observed for the 3 leading-edge proteins is shown for all subjects and timepoints measured, where

817 RFU indicates relative fluorescence units (right). Abbreviations: VSG: vertical sleeve
818 gastrectomy.

819 **SuppFig.1. Pre-VSG, microbiome diversity and composition related to Type 2 Diabetes**
820 **status differed, but resolved post-VSG.** (A) Subjects with established diabetes exhibited
821 significantly distinct bacterial microbiota diversity ($P < 0.05$). (B) Microbiota composition was
822 also highly distinct between subjects with established T2DM and those without (Bray Curtis
823 PERMANOVA $R^2=0.44$, $P = 0.001$). Abbreviations: VSG: vertical sleeve gastrectomy, T2DM:
824 type 2 diabetes mellitus, PERMANOVA: Permutational Analysis of Variance.

825 **SuppFig.2. Enzyme Commission genes found to be differentially abundant post-VSG formed**
826 **three distinct modules of co-associated genes.** (A) PCoA Plot of Enzyme Commission
827 composition using Canberra distance. R^2 and p-values are derived from PERMANOVA. (B)
828 Differentially abundant enzyme class post-VSG. Enzyme class to the left decrease post-VSG and
829 enzymes to the right increase post-VSG. (C) Hierarchical clustering representation of WGCNA
830 modules based on moderately differential (FDR $P < 0.4$) pre- and post-VSG. Identified modules
831 are represented by their color underneath the dendrogram. (D) All modules exhibited increases in
832 abundance post-VSG (LME $P < 0.01$). (E) Genera in the microbiome that contribute to each of the
833 three differentially abundant networks described in panels (C) and (D). Abbreviations: VSG:
834 vertical sleeve gastrectomy, FDR: False Discovery Rate, LME: Linear Mixed Effects, PCoA:
835 Principal Coordinates Analysis, PERMANOVA: Permutational Analysis of Variance, WGCNA:
836 Weighted Gene Co-Association Network Analysis.

837 **SuppFig.3. Metagenomic Viral Diversity and composition is not impacted by vertical sleeve**
838 **gastrectomy.** (A) Identified viruses were primarily comprised of Caudoviricetes. Donut plot
839 represents abundances across both pre-VSG (left) and post-VSG (right) samples for each

840 taxonomic category. (B) Host taxonomy of identified viruses including *Bacteroides*,
841 *Bacteroidaceae*, and *Prevotella*, as well as several with no known hosts. As in (A), plot represents
842 summarized abundances across both pre-VSG (left) and post-VSG (right) samples for each viral
843 host. (C) Viral taxonomic diversity does not change due to VSG with respect to either Chao1
844 richness or evenness. (D) Viral taxonomic composition does not change significantly due to VSG.
845 Exploration of either (E) viral Protein Family (PFAM) diversity or (F) composition did not reveal
846 significant differences due to VSG. Points indicate individual samples and lines connect paired
847 samples. P-values for diversity were generated from a linear mixed-effects model with the subject
848 as the random effect. Ellipses in composition plots represent 20% confidence intervals for each
849 group. PERMANOVA calculated the R^2 and p-values with the subject as the strata variable.
850 Abbreviations: VSG: vertical sleeve gastrectomy, PERMANOVA (Permutational Analysis of
851 Variance), PFAM (Protein Family).

852 **SuppFig.4.** Metabolites (circles) correlate with clinical variables (squares) (A) prior to and (B)
853 after VSG ($p < 0.05$). Pink lines indicate positive associations between metabolites and clinical
854 variables while blue lines indicate negative associations. Relationships were identified with non-
855 parametric statistics (Wilcox Rank-sum for binary variables and Spearman correlation for
856 continuous variables). Abbreviations: VSG: vertical sleeve gastrectomy, AA: Amino Acid, FA-
857 Car: Fatty Acid Carnitines, TCA: Tricarboxylic Acid, NT: Neurotransmitter, SCFA: Short Chain
858 Fatty Acid.

859 **SuppFig.5. Metabolites change in concert with networks of taxa.** (A) Taxa exhibiting at least
860 moderate change after VSG ($P \text{ FDR} < 0.5$) formed several co-associated networks using Weighted
861 Gene Co-Association Network Analysis (WGCNA). (B) These networks were characterized by
862 specific taxa that collectively changed in abundance. P-values were generated from linear mixed

863 effects models. (C) These differential networks changed in concert with several changing
864 metabolites. Each line indicates a significant Spearman correlation between the change of
865 metabolites (difference in value before and after) and the change in microbial taxa (difference in
866 mean abundance before and after). Positive correlations are indicated in pink and negative
867 correlations are indicated in blue. The weight of the line indicates the strength of the correlation.
868 Modules identified in panels (A) and (B) are noted by their characteristic taxa. Abbreviations:
869 VSG: vertical sleeve gastrectomy, AA: Amino Acid, FA-Car: Fatty Acid Carnitine, TCA:
870 Tricarboxylic Acid, NT: Neurotransmitter, SCFA: Short Chain Fatty Acid.

871 **SuppFig.6. Additional flow cytometry data of mice receiving FT with pre-VSG and post-VSG**
872 **stool.** (A) Gating strategy for lymphoid cells is shown. (B) Number of live lymphoid cells in the
873 large intestine lamina propria and mesenteric lymph node are plotted. (C-D). Number of live cells
874 for each of the CD4⁺ T cell subsets, their proportion in the mesenteric lymph node (C) and
875 proportion of cytokine producing CD4⁺ T cells (D) are plotted. Groups and participants are
876 identified as shown in the key in (B). Data are displayed as mean \pm standard error of the mean.
877 Statistical significance between pre-VSG and post-VSG groups was calculated using unpaired
878 Student's t-test and non-significance (ns) or p-values are indicated. (E) Top 10 Amplicon sequence
879 variants and flow cytometry features that discriminate pre-VSG vs post-VSG samples from each
880 subject used for FT (n=36 features) identified using mixOmics; rows are z-score scaled.
881 Abbreviations: FT: fecal transplant, VSG: vertical sleeve gastrectomy.

882 **SuppFig.7.** (A) PCoA plot representing the 6 subjects with increasing calprotectin values post-
883 VSG, in which post-VSG samples become more related to each other. PERMANOVA calculated
884 the interaction between before-vs-after VSG samples (time) and calprotectin. (B) Paired Distance
885 within Pre-VSG samples, within Post-VSG samples, and between Pre-VSG and Post-VSG

886 samples, showing that distance within Pre-VSG samples exhibit higher distance than distances
887 within Post-VSG samples. P-values calculated with Wilcoxon Rank-Sum Test.

888 **SuppFig.8.** Validation of urine proteomics against serum proteomics in a separate pediatric cohort.
889 The SomaScan Assay utilizes 7000 SOMAmer Reagents optimized for detection of proteins in
890 peripheral blood serum or plasma. To determine the subset that could be measured in urine,
891 SOMAmer Reagents were classified by comparing their average signal in a cohort of 53 urine
892 samples to background and saturation thresholds. SOMAmer Reagents with a signal-to-noise ratio
893 <1.7 (n=5705) or a saturating signal of RFU >80000 (n=35) were excluded. 1856 SOMAmer
894 Reagents remained within the detectable range of the assay when using urine in this cohort of
895 samples.

896 **Supp Table 1.** Excel file containing taxa enriched post-VSG, related to Figure 1.

897 **Supp Table 2.** Excel file containing CAZymes enriched post-VSG, post-VSG CAZymes related
898 to Total Body Weight Loss, Antibiotic Resistance Genes enriched post-VSG, related to Figure 2.

899 **Supp Table 3.** Excel file containing Enzyme Commission genes enriched post-VSG and
900 pathway enrichments of EC networks, related to Supplemental Figure 2.

901 **Supp Table 4.** Excel file containing pre-VSG and post-VSG correlations between metabolites
902 and clinical metadata, related to Supplemental Figure 4.

903 **Supp Table 5.** Excel file containing module assignments of bacterial taxa and correlations
904 between bacterial taxa module changes and metabolite changes, related to Supplemental Figure
905 5.

906

907

908 **ACKNOWLEDGEMENTS**

909 **DATA AVAILABILITY STATEMENT**

910 All data generated or analyzed during this study are included in this published article and its online
911 supplemental information files.

912 Sequencing reads for human and murine analyses are deposited in the Sequence Read Archive
913 (SRA) under accession number PRJNA1093424 at the following reviewer link:

914 <https://dataview.ncbi.nlm.nih.gov/object/PRJNA1093424?reviewer=gbe14pmjol31cvc64bn6vh4f>
915 [4r](#).

916 Metabolite data is deposited at
917 [https://figshare.com/articles/dataset/Supporting_data_for_bariatric_surgery_patient_fecal_metab](https://figshare.com/articles/dataset/Supporting_data_for_bariatric_surgery_patient_fecal_metabolomics_and_bile_acid_measurements/25864327)
918 [olomics_and_bile_acid_measurements/25864327](https://figshare.com/articles/dataset/Supporting_data_for_bariatric_surgery_patient_fecal_metabolomics_and_bile_acid_measurements/25864327).

919 This paper does not report original code.

920

921 **FUNDING**

922 This work was supported by the National Institute of Allergy and Infectious Diseases (NIAID) of
923 the National Institutes of Health under the Division of Intramural Research, NIAID, NIH
924 (Hourigan), BCBB Support Services Contract HHSN316201300006W/75N93022F00001 to
925 Medical Science & Computing (McCauley, Subramanian, McCauley), the Thrasher Research Fund
926 Early Career Award #01484 (Akagbosu), and the American Pediatric Association Research in
927 Academic Pediatrics Initiative on Diversity (RAPID) grant with funding from the National
928 Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Grant R25DK096944

929 (Akagbosu). The funders had no role in the design and conduct of the study; collection,
930 management, analysis, and interpretation of the data; preparation, review, or approval of the
931 manuscript; and decision to submit the manuscript for publication. The content is solely the
932 responsibility of the authors and does not necessarily represent the official views of the National
933 Institutes of Health.

934 The authors acknowledge the NCI Gnotobiotic Animal Facility Staff for their assistance in
935 performing the germ-free mice experiments. This work used the Office of Cyber Infrastructure
936 and Computational Biology High Performance Computing cluster at NIAID, Bethesda, MD and
937 the Center for Genetic Medicine Research in the Children's National Research Institute under Dr.
938 Robert Freishtat.

939 **AUTHOR CONTRIBUTIONS**

940 Cynthia O Akagbosu, Kathryn McCauley and Sivaranjani Namasivayam contributed equally to
941 this paper (first authors).

942 Evan P Nadler and Suchitra K Hourigan contributed equally to this paper (senior authors).

943 C.O.A., S.N., E.P.N. and S.K.H. conceived and designed the project. All authors acquired,
944 analyzed, or interpreted data from the study. K.E.M., S.N., H.N.R-S., M.B., B.S., Q.C. and F.C.
945 performed statistical analysis. C.O.A and S.K.H. obtained funding for the project. E.P.N and
946 S.K.H supervised the project. C.O.A., K.M., S.N., B.S. and S.K.H. wrote the original draft. All
947 authors reviewed and edited the manuscript, approved the final submitted manuscript and have
948 agreed both to be personally accountable for the author's own contributions and to ensure that
949 questions related to the accuracy or integrity of any part of the work, even ones in which the

950 author was not personally involved, are appropriately investigated, resolved, and the resolution
951 documented in the literature.

952 **ETHICS DECLARATIONS**

953 **Ethics approval and consent to participate:**

954 The study was approved by an Institutional Review Board (Children’s National Hospital IRB
955 protocol #Pro00015976) and all participants provided written informed consent ± assent to
956 participate.

957 **Declaration of interests:**

958 B.A.S. is a former SomaLogic, Inc. (Boulder, CO, USA) employee and a company shareholder.

959 All other authors declare that they have no competing interests.

960

961

962

963

964

965

966

967

968

969 **ABBREVIATIONS**

970 VSG: Vertical Sleeve Gastrectomy

971 T2DM: Type 2 Diabetes Mellitus

972 MASLD: metabolic dysfunction-associated steatotic liver disease

973 FT: Fecal transplant

974 GLP-1: Glucagon-like peptide-1

975 BMI: Body mass index

976 TBWL: Total body weight loss

977 ALT: Alanine aminotransferase

978 LDL: Low-density lipoprotein

979 HDL: High-density lipoprotein

980 CAZymes: Carbohydrate-Active Enzymes

981 ARG: Antibiotic resistance genes

982 EC: Enzyme Commission

983

984 SCFA: Short-chain fatty acids

985 HbA1c: Hemoglobin A1C

986 FC: Fecal Calprotectin

987 IBD: Inflammatory Bowel Disease

988

989

990

991

992

993

994

995

996

997 **REFERENCES**

- 998 1. National Institute of Diabetes and Digestive and Kidney Diseases Overweight & Obesity
999 Statistics|NIDDK 2021 [Available from: [https://www.niddk.nih.gov/health-](https://www.niddk.nih.gov/health-information/health-statistics/overweight-obesity)
1000 [information/health-statistics/overweight-obesity](https://www.niddk.nih.gov/health-information/health-statistics/overweight-obesity) accessed May 24 2024.
- 1001 2. Andes LJ, Cheng YJ, Rolka DB, et al. Prevalence of Prediabetes Among Adolescents and
1002 Young Adults in the United States, 2005-2016. *JAMA Pediatr* 2020;174(2):e194498. doi:
1003 10.1001/jamapediatrics.2019.4498 [published Online First: 20200203]
- 1004 3. Simmonds M, Llewellyn A, Owen CG, et al. Predicting adult obesity from childhood obesity:
1005 a systematic review and meta-analysis. *Obes Rev* 2016;17(2):95-107. doi:
1006 10.1111/obr.12334 [published Online First: 20151223]
- 1007 4. Juonala M, Magnussen CG, Berenson GS, et al. Childhood adiposity, adult adiposity, and
1008 cardiovascular risk factors. *N Engl J Med* 2011;365(20):1876-85. doi:
1009 10.1056/NEJMoa1010112
- 1010 5. Inge TH, Courcoulas AP, Jenkins TM, et al. Weight Loss and Health Status 3 Years after
1011 Bariatric Surgery in Adolescents. *N Engl J Med* 2016;374(2):113-23. doi:
1012 10.1056/NEJMoa1506699 [published Online First: 20151106]
- 1013 6. Pratt JSA, Browne A, Browne NT, et al. ASMBS pediatric metabolic and bariatric surgery
1014 guidelines, 2018. *Surg Obes Relat Dis* 2018;14(7):882-901. doi:
1015 10.1016/j.soard.2018.03.019 [published Online First: 20180323]
- 1016 7. Hampl SE, Hassink SG, Skinner AC, et al. Clinical Practice Guideline for the Evaluation and
1017 Treatment of Children and Adolescents With Obesity. *Pediatrics* 2023;151(2) doi:
1018 10.1542/peds.2022-060640
- 1019 8. Steinberger AE, Nickel KB, Keller M, et al. National Trends in Pediatric Metabolic and
1020 Bariatric Surgery: 2010-2017. *Pediatrics* 2022;150(6) doi: 10.1542/peds.2022-057316
- 1021 9. McCarty TR, Jirapinyo P, Thompson CC. Effect of Sleeve Gastrectomy on Ghrelin, GLP-1,
1022 PYY, and GIP Gut Hormones: A Systematic Review and Meta-analysis. *Ann Surg*
1023 2020;272(1):72-80. doi: 10.1097/sla.0000000000003614
- 1024 10. Crovesy L, Masterson D, Rosado EL. Profile of the gut microbiota of adults with obesity: a
1025 systematic review. *Eur J Clin Nutr* 2020;74(9):1251-62. doi: 10.1038/s41430-020-0607-6
1026 [published Online First: 20200330]
- 1027 11. Ridaura VK, Faith JJ, Rey FE, et al. Gut microbiota from twins discordant for obesity
1028 modulate metabolism in mice. *Science* 2013;341(6150):1241214. doi:
1029 10.1126/science.1241214
- 1030 12. Hamamah S, Hajnal A, Covasa M. Influence of Bariatric Surgery on Gut Microbiota
1031 Composition and Its Implication on Brain and Peripheral Targets. *Nutrients* 2024;16(7)
1032 doi: 10.3390/nu16071071 [published Online First: 20240405]
- 1033 13. Davies NK, O'Sullivan JM, Plank LD, et al. Altered gut microbiome after bariatric surgery
1034 and its association with metabolic benefits: A systematic review. *Surg Obes Relat Dis*
1035 2019;15(4):656-65. doi: 10.1016/j.soard.2019.01.033 [published Online First: 20190207]
- 1036 14. Akagbosu CO, Nadler EP, Levy S, et al. The Role of the Gut Microbiome in Pediatric
1037 Obesity and Bariatric Surgery. *Int J Mol Sci* 2022;23(23) doi: 10.3390/ijms232315421
1038 [published Online First: 20221206]
- 1039 15. Yatsunenkov T, Rey FE, Manary MJ, et al. Human gut microbiome viewed across age and
1040 geography. *Nature* 2012;486(7402):222-7. doi: 10.1038/nature11053 [published Online
1041 First: 2012/06/16]

- 1042 16. Hollister EB, Riehle K, Luna RA, et al. Structure and function of the healthy pre-adolescent
1043 pediatric gut microbiome. *Microbiome* 2015;3:36. doi: 10.1186/s40168-015-0101-x
1044 [published Online First: 20150826]
- 1045 17. Agans R, Rigsbee L, Kenche H, et al. Distal gut microbiota of adolescent children is different
1046 from that of adults. *FEMS Microbiol Ecol* 2011;77(2):404-12. doi: 10.1111/j.1574-
1047 6941.2011.01120.x [published Online First: 20110601]
- 1048 18. Shelton CD, Sing E, Mo J, et al. An early-life microbiota metabolite protects against obesity
1049 by regulating intestinal lipid metabolism. *Cell Host Microbe* 2023;31(10):1604-19.e10.
1050 doi: 10.1016/j.chom.2023.09.002 [published Online First: 20231003]
- 1051 19. Vu K, Lou W, Tun HM, et al. From Birth to Overweight and Atopic Disease: Multiple and
1052 Common Pathways of the Infant Gut Microbiome. *Gastroenterology* 2021;160(1):128-
1053 44.e10. doi: 10.1053/j.gastro.2020.08.053 [published Online First: 2020/09/19]
- 1054 20. Szczudlik E, Stępniewska A, Bik-Multanowski M, et al. The age of the obesity onset is a
1055 very important factor for the development of metabolic complications and cardiovascular
1056 risk in children and adolescents with severe obesity. *Eur J Pediatr* 2024 doi:
1057 10.1007/s00431-024-05636-x [published Online First: 20240615]
- 1058 21. Draijer L, Voorhoeve M, Troelstra M, et al. A natural history study of paediatric non-
1059 alcoholic fatty liver disease over 10 years. *JHEP Rep* 2023;5(5):100685. doi:
1060 10.1016/j.jhepr.2023.100685 [published Online First: 20230125]
- 1061 22. Tommerdahl KL, Kendrick J, Nelson RG, et al. Youth versus adult-onset type 2 diabetic
1062 kidney disease: Insights into currently known structural differences and the potential
1063 underlying mechanisms. *Clin Sci (Lond)* 2022;136(21):1471-83. doi:
1064 10.1042/cs20210627
- 1065 23. Wardman JF, Bains RK, Rahfeld P, et al. Carbohydrate-active enzymes (CAZymes) in the gut
1066 microbiome. *Nat Rev Microbiol* 2022;20(9):542-56. doi: 10.1038/s41579-022-00712-1
1067 [published Online First: 20220328]
- 1068 24. Farin W, Oñate FP, Plassais J, et al. Impact of laparoscopic Roux-en-Y gastric bypass and
1069 sleeve gastrectomy on gut microbiota: a metagenomic comparative analysis. *Surg Obes
1070 Relat Dis* 2020;16(7):852-62. doi: 10.1016/j.soard.2020.03.014 [published Online First:
1071 20200320]
- 1072 25. Paganelli FL, Luyer M, Hazelbag CM, et al. Roux-Y Gastric Bypass and Sleeve Gastrectomy
1073 directly change gut microbiota composition independent of surgery type. *Sci Rep*
1074 2019;9(1):10979. doi: 10.1038/s41598-019-47332-z [published Online First: 20190729]
- 1075 26. Porat D, Vaynshtein J, Gibori R, et al. Stomach pH before vs. after different bariatric surgery
1076 procedures: Clinical implications for drug delivery. *Eur J Pharm Biopharm*
1077 2021;160:152-57. doi: 10.1016/j.ejpb.2021.01.016 [published Online First: 20210130]
- 1078 27. Koutoukidis DA, Jebb SA, Zimmerman M, et al. The association of weight loss with changes
1079 in the gut microbiota diversity, composition, and intestinal permeability: a systematic
1080 review and meta-analysis. *Gut Microbes* 2022;14(1):2020068. doi:
1081 10.1080/19490976.2021.2020068
- 1082 28. Sidar A, Voshol GP, Vijgenboom E, et al. Novel Design of an α -Amylase with an N-Terminal
1083 CBM20 in *Aspergillus niger* Improves Binding and Processing of a Broad Range of
1084 Starches. *Molecules* 2023;28(13) doi: 10.3390/molecules28135033 [published Online
1085 First: 20230627]

- 1086 29. Liao C, Rolling T, Djukovic A, et al. Oral bacteria relative abundance in faeces increases due
1087 to gut microbiota depletion and is linked with patient outcomes. *Nat Microbiol* 2024 doi:
1088 10.1038/s41564-024-01680-3 [published Online First: 20240502]
- 1089 30. Read E, Curtis MA, Neves JF. The role of oral bacteria in inflammatory bowel disease. *Nat*
1090 *Rev Gastroenterol Hepatol* 2021;18(10):731-42. doi: 10.1038/s41575-021-00488-4
1091 [published Online First: 20210816]
- 1092 31. Sayols-Baixeras S, Dekkers KF, Baldanzi G, et al. Streptococcus Species Abundance in the
1093 Gut Is Linked to Subclinical Coronary Atherosclerosis in 8973 Participants From the
1094 SCAPIS Cohort. *Circulation* 2023;148(6):459-72. doi:
1095 10.1161/circulationaha.123.063914 [published Online First: 20230712]
- 1096 32. Wahlström A, Sayin SI, Marschall HU, et al. Intestinal Crosstalk between Bile Acids and
1097 Microbiota and Its Impact on Host Metabolism. *Cell Metab* 2016;24(1):41-50. doi:
1098 10.1016/j.cmet.2016.05.005 [published Online First: 20160616]
- 1099 33. Fragkos KC, Forbes A. Citrulline as a marker of intestinal function and absorption in clinical
1100 settings: A systematic review and meta-analysis. *United European Gastroenterol J*
1101 2018;6(2):181-91. doi: 10.1177/2050640617737632 [published Online First: 20171012]
- 1102 34. Crenn P, Messing B, Cynober L. Citrulline as a biomarker of intestinal failure due to
1103 enterocyte mass reduction. *Clin Nutr* 2008;27(3):328-39. doi: 10.1016/j.clnu.2008.02.005
1104 [published Online First: 20080428]
- 1105 35. Azizi S, Mahdavi R, Mobasser M, et al. The impact of L-citrulline supplementation on
1106 glucose homeostasis, lipid profile, and some inflammatory factors in overweight and
1107 obese patients with type 2 diabetes: A double-blind randomized placebo-controlled trial.
1108 *Phytother Res* 2021;35(6):3157-66. doi: 10.1002/ptr.6997 [published Online First:
1109 20210420]
- 1110 36. Eshreif A, Al Batran R, Jamieson KL, et al. L-Citrulline supplementation improves glucose
1111 and exercise tolerance in obese male mice. *Exp Physiol* 2020;105(2):270-81. doi:
1112 10.1113/ep088109 [published Online First: 20200115]
- 1113 37. Holguin F, Grasemann H, Sharma S, et al. L-Citrulline increases nitric oxide and improves
1114 control in obese asthmatics. *JCI Insight* 2019;4(24) doi: 10.1172/jci.insight.131733
1115 [published Online First: 20191219]
- 1116 38. Joffin N, Jaubert AM, Durant S, et al. Citrulline induces fatty acid release selectively in
1117 visceral adipose tissue from old rats. *Mol Nutr Food Res* 2014;58(9):1765-75. doi:
1118 10.1002/mnfr.201400053 [published Online First: 20140610]
- 1119 39. Strandwitz P. Neurotransmitter modulation by the gut microbiota. *Brain Res* 2018;1693(Pt
1120 B):128-33. doi: 10.1016/j.brainres.2018.03.015
- 1121 40. Blaner WS. Vitamin A signaling and homeostasis in obesity, diabetes, and metabolic
1122 disorders. *Pharmacol Ther* 2019;197:153-78. doi: 10.1016/j.pharmthera.2019.01.006
1123 [published Online First: 20190129]
- 1124 41. Juárez-Fernández M, Román-Sagüillo S, Porrás D, et al. Long-Term Effects of Bariatric
1125 Surgery on Gut Microbiota Composition and Faecal Metabolome Related to Obesity
1126 Remission. *Nutrients* 2021;13(8) doi: 10.3390/nu13082519 [published Online First:
1127 20210723]
- 1128 42. Anhê FF, Zlitni S, Zhang SY, et al. Human gut microbiota after bariatric surgery alters
1129 intestinal morphology and glucose absorption in mice independently of obesity. *Gut*
1130 2023;72(3):460-71. doi: 10.1136/gutjnl-2022-328185 [published Online First: 20220825]

- 1131 43. Yadav J, Liang T, Qin T, et al. Gut microbiome modified by bariatric surgery improves
1132 insulin sensitivity and correlates with increased brown fat activity and energy
1133 expenditure. *Cell Rep Med* 2023;4(5):101051. doi: 10.1016/j.xcrm.2023.101051
- 1134 44. Tremaroli V, Karlsson F, Werling M, et al. Roux-en-Y Gastric Bypass and Vertical Banded
1135 Gastroplasty Induce Long-Term Changes on the Human Gut Microbiome Contributing to
1136 Fat Mass Regulation. *Cell Metab* 2015;22(2):228-38. doi: 10.1016/j.cmet.2015.07.009
- 1137 45. Rohm TV, Meier DT, Olefsky JM, et al. Inflammation in obesity, diabetes, and related
1138 disorders. *Immunity* 2022;55(1):31-55. doi: 10.1016/j.immuni.2021.12.013
- 1139 46. Bianchi VE. Weight loss is a critical factor to reduce inflammation. *Clin Nutr ESPEN*
1140 2018;28:21-35. doi: 10.1016/j.clnesp.2018.08.007 [published Online First: 20180903]
- 1141 47. Fukuda N, Ojima T, Hayata K, et al. Laparoscopic sleeve gastrectomy for morbid obesity
1142 improves gut microbiota balance, increases colonic mucosal-associated invariant T cells
1143 and decreases circulating regulatory T cells. *Surg Endosc* 2022;36(10):7312-24. doi:
1144 10.1007/s00464-022-09122-z [published Online First: 20220219]
- 1145 48. Pang SS, Le YY. Role of resistin in inflammation and inflammation-related diseases. *Cell*
1146 *Mol Immunol* 2006;3(1):29-34.
- 1147 49. Taouis M, Benomar Y. Is resistin the master link between inflammation and inflammation-
1148 related chronic diseases? *Mol Cell Endocrinol* 2021;533:111341. doi:
1149 10.1016/j.mce.2021.111341 [published Online First: 20210531]
- 1150 50. Schnell A, Littman DR, Kuchroo VK. T(H)17 cell heterogeneity and its role in tissue
1151 inflammation. *Nat Immunol* 2023;24(1):19-29. doi: 10.1038/s41590-022-01387-9
1152 [published Online First: 20230103]
- 1153 51. Chen L, Ruan G, Cheng Y, et al. The role of Th17 cells in inflammatory bowel disease and
1154 the research progress. *Front Immunol* 2022;13:1055914. doi:
1155 10.3389/fimmu.2022.1055914 [published Online First: 20230109]
- 1156 52. Kaakoush NO. Insights into the Role of Erysipelotrichaceae in the Human Host. *Front Cell*
1157 *Infect Microbiol* 2015;5:84. doi: 10.3389/fcimb.2015.00084 [published Online First:
1158 20151120]
- 1159 53. Miyauchi E, Kim SW, Suda W, et al. Gut microorganisms act together to exacerbate
1160 inflammation in spinal cords. *Nature* 2020;585(7823):102-06. doi: 10.1038/s41586-020-
1161 2634-9 [published Online First: 20200826]
- 1162 54. Kawano Y, Edwards M, Huang Y, et al. Microbiota imbalance induced by dietary sugar
1163 disrupts immune-mediated protection from metabolic syndrome. *Cell*
1164 2022;185(19):3501-19.e20. doi: 10.1016/j.cell.2022.08.005 [published Online First:
1165 20220829]
- 1166 55. Westerink F, Huibregtse I, De Hoog M, et al. Faecal Inflammatory Biomarkers and
1167 Gastrointestinal Symptoms after Bariatric Surgery: A Longitudinal Study. *Inflamm Intest*
1168 *Dis* 2021;6(2):109-16. doi: 10.1159/000514576 [published Online First: 20210414]
- 1169 56. Serrano E, Bastard JP, Trystram L, et al. Serum Versus Fecal Calprotectin Levels in Patients
1170 with Severe Obesity Before and 6 Months After Roux-Y-Gastric Bypass: Report of the
1171 Prospective Leaky-Gut Study. *Obes Surg* 2023;33(12):4017-25. doi: 10.1007/s11695-
1172 023-06911-w [published Online First: 20231104]
- 1173 57. Liu T, Zhang L, Joo D, et al. NF- κ B signaling in inflammation. *Signal Transduct Target Ther*
1174 2017;2:17023-. doi: 10.1038/sigtrans.2017.23 [published Online First: 20170714]
- 1175 58. Atreya I, Atreya R, Neurath MF. NF-kappaB in inflammatory bowel disease. *J Intern Med*
1176 2008;263(6):591-6. doi: 10.1111/j.1365-2796.2008.01953.x

- 1177 59. Sokol H, Pigneur B, Watterlot L, et al. Faecalibacterium prausnitzii is an anti-inflammatory
1178 commensal bacterium identified by gut microbiota analysis of Crohn disease patients.
1179 *Proc Natl Acad Sci U S A* 2008;105(43):16731-6. doi: 10.1073/pnas.0804812105
1180 [published Online First: 20081020]
- 1181 60. Rahman MM, McFadden G. Modulation of NF- κ B signalling by microbial pathogens. *Nat*
1182 *Rev Microbiol* 2011;9(4):291-306. doi: 10.1038/nrmicro2539 [published Online First:
1183 20110308]
- 1184 61. Giri R, Hoedt EC, Khushi S, et al. Secreted NF- κ B suppressive microbial metabolites
1185 modulate gut inflammation. *Cell Rep* 2022;39(2):110646. doi:
1186 10.1016/j.celrep.2022.110646
- 1187 62. Igwe JK, Surapaneni PK, Cruz E, et al. Bariatric Surgery and Inflammatory Bowel Disease:
1188 National Trends and Outcomes Associated with Procedural Sleeve Gastrectomy vs
1189 Historical Bariatric Surgery Among US Hospitalized Patients 2009-2020. *Obes Surg*
1190 2023;33(11):3472-86. doi: 10.1007/s11695-023-06833-7 [published Online First:
1191 20231007]
- 1192 63. Kiasat A, Granström AL, Stenberg E, et al. The risk of inflammatory bowel disease after
1193 bariatric surgery. *Surg Obes Relat Dis* 2022;18(3):343-50. doi:
1194 10.1016/j.soard.2021.12.014 [published Online First: 20211217]
- 1195 64. Braga Neto MB, Gregory M, Ramos GP, et al. De-novo Inflammatory Bowel Disease After
1196 Bariatric Surgery: A Large Case Series. *J Crohns Colitis* 2018;12(4):452-57. doi:
1197 10.1093/ecco-jcc/jjx177
- 1198 65. Glassner KL, Abraham BP, Quigley EMM. The microbiome and inflammatory bowel
1199 disease. *J Allergy Clin Immunol* 2020;145(1):16-27. doi: 10.1016/j.jaci.2019.11.003
1200 [published Online First: 2020/01/09]
- 1201 66. Ramamoorthy S, Levy S, Mohamed M, et al. An ambient-temperature storage and
1202 stabilization device performs comparably to flash-frozen collection for stool
1203 metabolomics in infants. *BMC Microbiol* 2021;21(1):59. doi: 10.1186/s12866-021-
1204 02104-6 [published Online First: 2021/02/24]
- 1205 67. FastQC: A Quality Control Tool for High Throughput Sequence Data [Online] [program].
1206 0.11.9 version: Babraham Bioinformatics, 2010.
- 1207 68. Ewels P, Magnusson M, Lundin S, et al. MultiQC: summarize analysis results for multiple
1208 tools and samples in a single report. *Bioinformatics* 2016;32(19):3047-8. doi:
1209 10.1093/bioinformatics/btw354 [published Online First: 20160616]
- 1210 69. Angelova A DD, Subramanian P, Quiñones M, Dolan M, Hurt DE. WGS A2 workflow - a
1211 tutorial. *protocolsio* 2023 doi: doi:10.17504/protocols.io.n921dm98xl5b/v1
- 1212 70. Weber N, Liou D, Dommer J, et al. Nephele: a cloud platform for simplified, standardized
1213 and reproducible microbiome data analysis. *Bioinformatics* 2018;34(8):1411-13. doi:
1214 10.1093/bioinformatics/btx617
- 1215 71. Chen S, Zhou Y, Chen Y, et al. fastp: an ultra-fast all-in-one FASTQ preprocessor.
1216 *Bioinformatics* 2018;34(17):i884-i90. doi: 10.1093/bioinformatics/bty560
- 1217 72. Wood DE, Lu J, Langmead B. Improved metagenomic analysis with Kraken 2. *Genome Biol*
1218 2019;20(1):257. doi: 10.1186/s13059-019-1891-0 [published Online First: 20191128]
- 1219 73. Nurk S, Meleshko D, Korobeynikov A, et al. metaSPAdes: a new versatile metagenomic
1220 assembler. *Genome Res* 2017;27(5):824-34. doi: 10.1101/gr.213959.116 [published
1221 Online First: 20170315]

- 1222 74. Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. *Nat Methods*
1223 2012;9(4):357-9. doi: 10.1038/nmeth.1923 [published Online First: 20120304]
- 1224 75. Cantalapiedra CP, Hernández-Plaza A, Letunic I, et al. eggNOG-mapper v2: Functional
1225 Annotation, Orthology Assignments, and Domain Prediction at the Metagenomic Scale.
1226 *Mol Biol Evol* 2021;38(12):5825-29. doi: 10.1093/molbev/msab293
- 1227 76. Zhu Q, Fisher SA, Shallcross J, et al. VERSE: a versatile and efficient RNA-Seq read
1228 counting tool. *bioRxiv* 2016:053306. doi: 10.1101/053306
- 1229 77. Zheng J, Ge Q, Yan Y, et al. dbCAN3: automated carbohydrate-active enzyme and substrate
1230 annotation. *Nucleic Acids Res* 2023;51(W1):W115-w21. doi: 10.1093/nar/gkad328
- 1231 78. Camargo AP, Roux S, Schulz F, et al. Identification of mobile genetic elements with
1232 geNomad. *Nat Biotechnol* 2024;42(8):1303-12. doi: 10.1038/s41587-023-01953-y
1233 [published Online First: 20230921]
- 1234 79. Zhu Q, Fisher S, Shallcross J, et al. VERSE: a versatile and efficient RNA-Seq read counting
1235 tool: *bioRxiv*, 2016.
- 1236 80. Nayfach S, Camargo AP, Schulz F, et al. CheckV assesses the quality and completeness of
1237 metagenome-assembled viral genomes. *Nat Biotechnol* 2021;39(5):578-85. doi:
1238 10.1038/s41587-020-00774-7 [published Online First: 20201221]
- 1239 81. Shaffer M, Borton MA, McGivern BB, et al. DRAM for distilling microbial metabolism to
1240 automate the curation of microbiome function. *Nucleic Acids Res* 2020;48(16):8883-900.
1241 doi: 10.1093/nar/gkaa621
- 1242 82. Steinegger M, Söding J. MMseqs2 enables sensitive protein sequence searching for the
1243 analysis of massive data sets. *Nat Biotechnol* 2017;35(11):1026-28. doi:
1244 10.1038/nbt.3988 [published Online First: 20171016]
- 1245 83. Guo J, Bolduc B, Zayed AA, et al. VirSorter2: a multi-classifier, expert-guided approach to
1246 detect diverse DNA and RNA viruses. *Microbiome* 2021;9(1):37. doi: 10.1186/s40168-
1247 020-00990-y [published Online First: 2021/02/02]
- 1248 84. Roux S, Camargo AP, Coutinho FH, et al. iPHoP: An integrated machine learning framework
1249 to maximize host prediction for metagenome-derived viruses of archaea and bacteria.
1250 *PLoS Biol* 2023;21(4):e3002083. doi: 10.1371/journal.pbio.3002083 [published Online
1251 First: 20230421]
- 1252 85. McMurdie PJ, Holmes S. phyloseq: an R package for reproducible interactive analysis and
1253 graphics of microbiome census data. *PLoS One* 2013;8(4):e61217. doi:
1254 10.1371/journal.pone.0061217 [published Online First: 20130422]
- 1255 86. Kuznetsova A, Brockhoff, P. B., & Christensen, R. H. B. lmerTest Package: Tests in Linear
1256 Mixed Effects Models. *Journal of Statistical Software* 2017;82(13):1-26. doi:
1257 10.18637/jss.v082.i13
- 1258 87. Oksanen J BF, Kindt R, Legendre P, Minchin P, O'Hara B, Simpson G, Solymos P, Stevens
1259 H, Wagner H. Vegan: Community Ecology Package. 2022
- 1260 88. Wickham H. ggplot2: Elegant Graphics for Data Analysis.: Wickham, H. ggplot2: Elegant
1261 Graphics for Data Analysis. 2016.
- 1262 89. Mallick H, Rahnavard A, McIver LJ, et al. Multivariable association discovery in population-
1263 scale meta-omics studies. *PLoS Comput Biol* 2021;17(11):e1009442. doi:
1264 10.1371/journal.pcbi.1009442 [published Online First: 20211116]
- 1265 90. Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis.
1266 *BMC Bioinformatics* 2008;9:559. doi: 10.1186/1471-2105-9-559 [published Online First:
1267 20081229]

- 1268 91. Rahnavard A, Mann B, Giri A, et al. Metabolite, protein, and tissue dysfunction associated
1269 with COVID-19 disease severity. *Sci Rep* 2022;12(1):12204. doi: 10.1038/s41598-022-
1270 16396-9 [published Online First: 20220716]
- 1271 92. Zeng M, Cao H. Fast quantification of short chain fatty acids and ketone bodies by liquid
1272 chromatography-tandem mass spectrometry after facile derivatization coupled with
1273 liquid-liquid extraction. *J Chromatogr B Analyt Technol Biomed Life Sci* 2018;1083:137-
1274 45. doi: 10.1016/j.jchromb.2018.02.040 [published Online First: 2018/03/17]
- 1275 93. Jaochico A, Sangaraju D, Shahidi-Latham SK. A rapid derivatization based LC-MS/MS
1276 method for quantitation of short chain fatty acids in human plasma and urine. *Bioanalysis*
1277 2019;11(8):741-53. doi: 10.4155/bio-2018-0241 [published Online First: 2019/04/18]
- 1278 94. McCloskey D, Gangoiiti JA, Palsson BO, et al. A pH and solvent optimized reverse-phase
1279 ion-pairing-LC-MS/MS method that leverages multiple scan-types for targeted absolute
1280 quantification of intracellular metabolites. *Metabolomics* 2015;11(5):1338-50. doi:
1281 10.1007/s11306-015-0790-y
- 1282 95. Prinville V, Ohlund L, Sleno L. Targeted Analysis of 46 Bile Acids to Study the Effect of
1283 Acetaminophen in Rat by LC-MS/MS. *Metabolites* 2020;10(1) doi:
1284 10.3390/metabo10010026 [published Online First: 2020/01/16]
- 1285 96. Sergushichev AA. An algorithm for fast preranked gene set enrichment analysis using
1286 cumulative statistic calculation. *bioRxiv* 2016:060012. doi: 10.1101/060012
- 1287 97. Cheung F, Fantoni G, Conner M, et al. Web Tool for Navigating and Plotting SomaLogic
1288 ADAT Files. *J Open Res Softw* 2017;5 doi: 10.5334/jors.166 [published Online First:
1289 20170908]
- 1290 98. Kozich JJ, Westcott SL, Baxter NT, et al. Development of a dual-index sequencing strategy
1291 and curation pipeline for analyzing amplicon sequence data on the MiSeq Illumina
1292 sequencing platform. *Appl Environ Microbiol* 2013;79(17):5112-20. doi:
1293 10.1128/aem.01043-13 [published Online First: 20130621]
- 1294 99. Callahan BJ, McMurdie PJ, Rosen MJ, et al. DADA2: High-resolution sample inference
1295 from Illumina amplicon data. *Nat Methods* 2016;13(7):581-3. doi: 10.1038/nmeth.3869
1296 [published Online First: 2016/05/24]
- 1297 100. Rohart F, Gautier B, Singh A, et al. mixOmics: An R package for 'omics feature selection
1298 and multiple data integration. *PLoS Comput Biol* 2017;13(11):e1005752. doi:
1299 10.1371/journal.pcbi.1005752 [published Online First: 20171103]

1300

1301

1302

1303

1304

1305





1306

1307

1308 **Table 1: Subject demographics, clinical data, and changes with laparoscopic vertical sleeve**
 1309 **gastrectomy (VSG). Significant p-values in bold.**






	Pre-VSG (n=12)	Post-VSG (n=12)	P-value
Demographics			
Age in years, mean (range)	15 (10-18)		
Female Sex	8 (67%)		
Race:			
White or Caucasian	2 (17%)		
Black or African American	9 (75%)		
Other	1 (8%)		
Hispanic or Latino Ethnicity	1 (8%)		
Clinical			
Body mass index (BMI), kg/m ²	48.7	39.9	<0.0001
Weight in kg, mean (range)	144 (94-195)	120 (67-173)	<0.0001
Diabetes or Prediabetes	8 (3 with diabetes, 5 with prediabetes)	0	0.0078
Dyslipidemia	4	1	0.25
Hypertension	4	3	1
HbA1c % (range)	5.6 (5.3-5.9)	5.2 (4.9-5.5)	0.0029
Low-density lipoprotein cholesterol mg/dL (range)	100.9 (64-157)	90.4 (66-126)	0.947
High-density lipoprotein cholesterol mg/dL (range)	41.3 (29-58)	49 (42-61)	0.0317
Triglycerides mg/dL (range)	111.5 (56-195)	81 (39-114)	0.271
Alanine aminotransferase U/L (range)	28.2 (9-59)	15.7 (6-28)	0.0025


1310
 1311
 1312
 1313
 1314
 1315
 1316
 1317
 1318
 1319
 1320





Time Point ● Pre-VSG ● Post-VSG

C Pre-VSG Post-VSG











B All subjects




Increased subjects only



C

Significant Enrichments for Pre-VSG vs Post-VSG



Pathways: IRAK2 mediated activation of TAK1 complex; TICAM1, TRAF6-dependent induction of TAK1 complex; IRAK1 recruits IKK complex; IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation

